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Acetylcholine (ACh) has been shown to have a neuroprotective effect against
glutamate-induced excitotoxicity in cultured retinal ganglion cells (RGCs) through
activation of α7 nicotinic ACh receptors (nAChRs). In this study, the neuroprotective
effects of the α7 nAChR agonist, PNU-282987, were investigated using an in vivo
model of glaucoma in adult Long Evans rats. Hypertonic saline injections were used
to induce a glaucoma model. After one month, retinas were removed, flat mounted,
fixed and labeled with an antibody against Thy 1.1 to label RGCs and fluorescently
tagged for visualization. Eye drop application of PNU-282987 resulted in
neuroprotection against RGC loss in a dose-dependent manner compared to untreated
controls when applied 3 days before hypertonic injections and for 30 days following
the procedure. Liquid chromatography with mass spectroscopy with quad capabilities
(LC/MSMS) demonstrated that PNU-282987 can be detected in the retina with small
amounts in blood plasma and no detectable levels in heart samples. These results
support the hypothesis that eye drop application of the α7 nAChR agonist, PNU282987, can prevent loss of RGCs associated under glaucoma-like conditions.
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SPECIFIC AIMS

Glaucoma is characterized as a neuropathic disease caused by an increase in
intraocular pressure (IOP) that causes damage to the optic nerve and progressive
degeneration of retinal ganglion cells (RGCs), resulting in a loss of vision (Guo et al.,
2005). In previous studies from Iwamoto (2011), the loss of RGCs was prevented in
an in-vivo rat model of glaucoma by using intravitreal injections of a specific α7
nicotinic acetylcholine receptor agonist (α7 nAChR), PNU-282987, before hypertonic
injections to induce glaucoma-like conditions. In this model, glaucoma-like
conditions were induced in the right eye of anesthetized Long Evans rats using
hypertonic injections of 2M saline into the episcleral veins of the eyes, which create
scar tissue and cause an increase in IOP to mimic glaucoma-like conditions. Previous
studies observed that significant loss of RGCs in the retina occurs one month
following hypertonic injections and the IOP increases gradually by an average of 12
mmHg. Retinal ganglion cell death resulted after injection of hypertonic saline unless
intravitreal injections of PNU-282987 were given prior to the hypertonic injections.
However, the use of intravitreal injections to eliminate the effects of glaucoma
is an invasive procedure and reduces the appeal of developing PNU-282987 as a
possible glaucoma treatment. This issue might be addressed by development of eye
drop applications. The hypothesis of this thesis is that eye drop applications of a
specific α7 nicotinic acetylcholine receptor agonist can prevent loss of retinal
ganglion cells in an in-vivo rat glaucoma model.
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INTRODUCTION

The eye is a highly developed sensory organ that allows the body to react to
the environment and to communicate with our surroundings.

Like many other

sensory organs, the eye works in profound ways to transduce energy into a
recognizable message that allows us to react to specific stimuli from the environment.
Signal transduction, which occurs in the retina, is the first step leading to visual
perception and is required for the visual process. The retina is composed of many
different cell types that work together to create and send electrical messages to the
brain, which ultimately leads to visual perception. Because of the physiological
importance of the retina for quality of life, there is a high priority in promoting ocular
health and research in retinal function. As this thesis involves an understanding of the
vertebrate retina, a brief description of the anatomy of the eye is included.

The Eye

The eye contains many anatomical features that are important for its function.
The cornea is the first lens of the optic system and functions to refract rays of light
from the environment to the retina (Jacob, 1823; Maycock, 1932). Light passes
through the cornea, which refracts rays of light and enters through the pupil in the
anterior chamber of the eye. The iris is the smooth muscle in the eye that controls how
much light is allowed in by controlling pupil diameter (Jacob, 1823; Maycock, 1932).
After the light passes through the pupil, it is further focused by the lens onto the retina
lying in the back of the posterior chamber of the eye (Jacob, 1823; Maycock, 1932).
2

The Retina

The vertebrate retina contains five main types of sensory neurons that work
together to detect light stimuli from the environment. The five main cell types in the
retina include; photoreceptors, horizontal cells, bipolar cells, amacrine and retinal
ganglion cells (Dowling, 1967; Werbin and Dowling, 1969). As light is focused onto
the retina from the lens, photoreceptors transduce incoming light into electric
potentials in the nervous system. Photoreceptors are responsible for carrying out
phototransduction, a process where photons of light are converted to electrical energy
so the brain can interpret visual stimuli (Tomita, 1970; Baylor and Fattiplace, 1977).
When photoreceptors are stimulated by light, pigments in the outer discs of these
neurons are stimulated to initiate a series of events that result in photoreceptor
hyperpolarization (Werbin and Dowling, 1969; Tomita, 1970; Kaneko, 1970). In the
dark, photoreceptors remain depolarized. This constant depolarization is called the
“dark current” (Hagins et al., 1970; Baylor et al., 1979). However, photoreceptors do
not play an important role in this study and will not be mentioned further.
The next step in the visual pathway is communication from primary receptors
to post-synaptic sensory neurons in the rest of the retinal circuitry. Photoreceptors
form synapses with bipolar cells (Dowling, 1967; Werbin and Dowling, 1969; Baylor
and Fettiplace, 1977). The synapse onto bipolar cells continues the direct electrical
pathway to retinal ganglion cells (RGCs) (Hartline, 1938; Kaneko, 1970; Baylor and
Fettiplace, 1977). The RGCs then relay visual information through the optic nerve to
the occipital lobe where the first stages of visual perception takes place (Hartline,
3

1938; Baylor and Fettiplace, 1977). Between the photoreceptors and RGCs, horizontal
and amacrine cells use lateral inhibition to enhance contrast differences before
information is sent to the brain (Kaneko, 1970; Cervetto and Piccolino, 1974;
Walonga and Pak, 1975; Kaneko and Shimazaki, 1975). As bipolar and horizontal
cells are not the focal point of this study, their physiology will not be described in
detail.

Amacrine Cells

One type of sensory neuron in the retina that will be discussed in this study is
amacrine cells. Amacrine cells were initially described by Cajal (1892), Famiglietti
(1983) and Masland (1988).

These cells are an extremely diverse class of

interneurons in the retina and more than two dozen morphologically distinct subtypes
have been described (Cajal, 1892; Kidd, 1962; Dowling and Boycott, 1966; Grimes,
2011). The particular subtype of amacrine cell that is pertinent to this study is known
as starburst amacrine cells. Starburst amacrine cells communicate with RGCs using
acetylcholine (ACh) (Famiglietti, 1983; Massland, 1988; Grimes, 2011). The possible
roles of starburst amacrine cells in this study will be elaborated upon when discussing
neurotransmitter function in the retina.

Retinal Ganglion Cells

RGCs are the main focus of this study. Hartline (1938) made significant
contributions to what is currently known about the physiology of the RGCs. RGCs are
4

essential for visual characterizations such as contrast detection and spatial sensitivity
(Hartland, 1938; Kuffler, 1953; Rodieck, 1965; Sharpley and Victor, 1986). RGCs, by
virtue of their response properties to photoreceptors, are also specialized to respond
preferentially to certain intensities of light and interpret rates of change in light
intensity (Kuffler, 1953; Barlow and Hill, 1963). This characteristic is important for
motion detection (Barlow and Hill, 1963).
RGCs are the final sensory neurons in the retina (Dowling, 1967; Werbin and
Dowling, 1969). The axons of the RGCs (along with glial components) make up the
optic nerve that leads to the occipital lobe where visual perception is initiated. RGCs
can be susceptible to various ocular diseases, such as glaucoma, that can affect visual
processing. This is a primary focus of this study.
There is much to understand about RGCs and RGC neuropathies. To
understand the RGCs neuropathies that can develop, it is important to understand the
RGC channels and neurotransmitters in the retina that activate specific receptors.
These

neurotransmitters

and

receptors

play

a

significant

role

in

many

neurodegenerative diseases, including glaucoma, that cause degeneration of RGCs. A
brief overview of neurotransmitters and receptors are mentioned below.

Neurotransmitters and Receptors in the Retina

There are many different types of neurotransmitters and receptors that are
released by neurons in the vertebrate retina (Yazulla, 1986; Ehinger et al., 1988;
Stryer, 1988; Marc et al., 1990). In the dark, photoreceptors release glutamate (Werbin
and Dowling, 1969; Marc et al., 1990; Jujich and Pourcho, 1996). This release of
5

glutamate from photoreceptors activates receptors located on bipolar cells. Bipolar
cells in turn release glutamate onto the RGCs and the electrical signals continue to the
brain (Ehinger et al, 1988; Marc et al., 1990; Jujich and Pourcho, 1996). Signals
throughout the retinal circuitry are modified by a process called lateral inhibition that
increases contrast detection (Kuffler, 1953; Barlow and Hill, 1963). This process is
achieved by horizontal and amacrine cells by the release of gamma-aminobutyric acid
(GABA) and glycine (Yazulla, 1986, Stryer, 1988, Marc et al., 1995) to inhibit
neighboring signals. In this thesis study, the release of glutamate and ACh in the retina
will be examined.

Glutamate

In the retina, photoreceptors, bipolar cells and RGCs release glutamate as their
primary small molecule neurotransmitter (Ehinger et al, 1988; Marc et al., 1990;
Gilbertson et al. 1991; Jujich and Pourcho, 1996). Glutamate can cause a
depolarization or hyperpolarization in bipolar cells depending on their type (Werbin
and Dowling, 1969; Baylor and Fettiplace, 1977). Glutamate receptors are classified
as ionotropic or metabotropic receptors (Mayer and Westbrook, 1987). There are three
main ionotropic receptors for glutamate; AMPA (α-amino-3-hydroxy-5-methyl-4isoxazolepropionic acid), kainate, and NMDA (N-Methyl-D-aspartate) receptors
(Mayer and Westbrook, 1987). AMPA and kainate glutamate receptors are collectively
called non-NMDA receptors (Mayer and Westbrook, 1987). OFF bipolar cells contain
AMPA and NMDA receptors, which are responsible for the depolarizing response
from glutamate (Gilbertson et al., 1991). The ON bipolar cells contain metabotropic
6

glutamate receptors and are responsible for the hyperpolarizing response (Pin and
Duvoisin, 1995). In this study, glutamate is key neurotransmitter proposed to be
involved in RGC cell death by over-stimulation of receptors.

Acetylcholine

ACh is found in starburst amacrine cells of the retina and was originally
characterized by Cajal (1892), Famiglietti (1983) and Massland (1988). Starburst
amacrine cells are the only cells in the retina known to synthesize and release ACh
onto RGCs. Both muscarinic and nicotinic ACh receptors (nAChRs) have been
demonstrated on RGCs in the mammalian retina (Keyser et al. 1988, Hughes, 1991).
Multiple subunits of nAChRs have been cloned (Sargent, 1993; McGehee et al., 1995;
Elliott et al., 1996). Under physiological condition, these subunits form heteromeric
and homomeric combinations (Sargent, 1993; McGehee et al., 1995). In the central
nervous system (CNS), the most common combination of nAChR subunits consist of
heteromeric α4-β2 subunits and homomeric α7 subunits (Elliot et al., 1996). Previous
studies done by Thompson et al. (2006) observed that both of these functional
nAChRs are found on pig RGCs. Furthermore, Iwamoto et al. (2013) demonstrated
that the homomeric α7 nAChR is found on rat RGCs.
During early development, starburst amacrine cells are necessary for
generation of retinal waves due to the excitatory effect of ACh release (Zhang et al.,
2004; Massland, 2011). The results from this thesis suggest that there may be an
additional function for ACh in the adult retina.

7

Glaucoma

In this study, glaucoma-like conditions were modeled in Long Evans rats to
provide an insight into the manifestation and possible prevention of the disease.
Currently, all treatments for glaucoma aim to reduce an increase of intraocular
pressure (IOP), which is the primary risk factor associated with glaucoma. However,
these treatments alone are insufficient to halt the progression of blindness associated
with glaucoma. Cell death correlated with over-stimulation of receptors has been
known to be associated with glaucoma, as well as other neurodegenerative diseases in
the CNS, and may provide a mechanism associated with the manifestation of the
disease (Choi, 1988; Tielsch et al., 1991; Gupta and Weinreb, 1997).
Currently, there are approximately 60 million people worldwide with
glaucoma. An estimated 8.4 million people are blinded by glaucoma. These numbers
are expected to increase to 80 million by 2020 (Cook and Foster, 2012). Glaucoma is
characterized as a progressive neurodegenerative disease that targets retinal
components (Foster et al., 1992). Neuropathy in glaucoma specifically targets the
axons of RGCs that make up the optic nerve (Foster et al., 1992). The axons and
somata from RGCs slowly degenerate under glaucoma-like conditions. This, in turn,
causes progressive loss of vision that lead to blindness in the individual. Glaucoma
patients tend to initially develop loss of visual function in the periphery and slowly
develop tunnel vision that becomes worse over time due to the cupping effect of the
disease (Madeiros et al., 2009; Hendry et al., 2012). This progressive tunnel vision
ultimately leads to blindness in individuals, if the disease is not treated. Blindness
caused by glaucoma is irreversible. Once adult neurons in the mammalian retina are
8

lost, there is no known method or treatment to regenerate them in-situ.
Causes for glaucoma are unclear. Because of this, the manifestations of
glaucoma are not well understood. Although there is a small genetic influence for
glaucoma cases (Fingert, 2011), there are two variations of glaucoma that are not due
to these genetic conditions, specifically open-angle and closed-angle glaucoma. Openangle glaucoma, the most common type of the disease, is likely associated with the
gradual congestion of the trabecular meshwork, disturbing the inflow and outflow of
aqueous humor in the anterior portion of the eye (Glaucoma Research Foundation,
2012). The other major type of glaucoma, closed-angle glaucoma, arises very quickly
and damage is usually very noticeable. Onset of closed-angle glaucoma can cause
symptoms of pain and if not treated immediately, can quickly result in blindness
(Glaucoma Research Foundation, 2012).
Several studies have demonstrated an association between loss of RGCs and
an increase in IOP under glaucoma-like conditions (Morrison et al., 1997; Chauhan et
al., 2002; Levkovitch-Verbin et al., 2002). The eye contains two chambers, the
anterior and posterior chamber, which is filled with aqueous and vitreous humor,
respectively. The aqueous humor is continually produced by the ciliary body and is
filtered through the trabecular meshwork as it exits the eye (Jocson and Sears, 1971;
Bill and Phillips 1971; Gelatt et al., 1977). In glaucoma, it has been observed that the
outflow system becomes congested, decreasing aqueous drainage (Jocson and Sears,
1971; Bill and Phillips 1971; Gelatt et al. 1977). Since the input of aqueous humor to
the anterior chamber continues, decreased drainage leads to increased pressure in the
anterior chamber (Gelatt et al., 1977). The retina can be the target of this increase in
pressure. As the pressure increases in the anterior chamber it continues to be conveyed
9

to the posterior chamber where vitreous humor is pushed through the optic nerve head
(ONH) causing cupping of the ONH. There is concomitant death of RGCs at this
point. The mechanism(s) behind this particular manifestation of glaucoma remains
debatable and is the topic of much discussion.
Today, there are two main treatments for glaucoma; medication or optic
surgery. These treatments ultimately focus on controlling the increase of IOP that
accompanies glaucoma (Damji et al., 2003). Drugs can be administered to decrease
the production of aqueous humor or can be administered to increase the drainage of
fluid in the trabecular meshwork. Both methods act to reduce the IOP (Damji et al.,
2003). These drugs can be administered topically or orally. Surgical procedures are
also used to control aqueous flow through the trabecular meshwork when medication
is not sufficient to lower IOP. Surgical procedures to lower IOP include cutting small
holes in the eye to drain the aqueous humor. Alternatively, lasers can be used to
produce holes in the trabecular meshwork to increase outflow of aqueous humor
(Cairns, 1968).
Glaucoma in its early stages is typically asymptomatic. Symptoms do not
typically begin until retinal damage causes peripheral vision loss. Often, by the time
patients receive medical care, the disease has progressed, some already partially blind.
These advanced stages of the disease decrease the chance of slowing the progression
of the disease (Cronenmberger et al, 2009). This is a particular problem in developing
countries where medical care is not easily accessible or affordable. Numerous studies
have reported that many patients know nothing about ocular diseases at the time they
receive medical care (Costa, 1995; Mello, 2003). For this reason, early detection of
this disease is essential if there is to be any success in slowing down the rapid
10

progression of optic nerve damage. The rapid degeneration of RGCs and optic nerve
are believed to be multi-factorial. One of these factors involves cell death caused by
over-stimulation of receptors.

Cell Death Caused by Over-stimulation of Receptors

One way that cell death can occur is by over-stimulation of receptors due to
excessive abundance of ligands in the extracellular space (Olney et al., 1977;
Michaelis, 1998). This over activation of receptors allows excessive influx of ions,
such as calcium, into cells which can lead to activation of apoptotic pathways. Overstimulation of these receptors has been correlated to many neuronal diseases including
Parkinson’s, Alzheimer’s and glaucoma (Quigley, 1998, Choi., 1998, Lafuente et al.,
2001).
Glutamate is the main neurotransmitter that is released from photoreceptors
and bipolar cells in the retina (Ehinger et al, 1988; Marc et al., 1990; Jujich and
Pourcho, 1996). Excessive glutamate release in the retina has been hypothesized to
trigger RGC loss associated with glaucoma (Onley, 1969; Neal et al., 1994; Vickers et
al., 1995; Kaushik, 2003). It has been observed that when pressure increases in the
anterior chamber of the eye, cells in the retina begin to release an excess of
neurotransmitter as cells in the retina begin to degenerate. As more glutamate is
released from dying cells, it leads to further over-stimulating of receptors on RGCs,
(Onley, 1969, Choi, 1987, Neal et al., 1994, Zhang et al., 2004 and Levkovitch-Verbin
et al., 2002). When non-specific cation NMDA channels allow an excess of calcium
influx into cells, intracellular calcium levels can rise to a point where apoptosis is
11

triggered through activation of protein kinases involved in apoptotic and cell death
pathways (Olney, 1977; Choi, 1987; Manev et al., 1989). The over-stimulation of
glutamate receptors has also been shown to regulate enzymes that break down cellular
structures associated with apoptotic events (Zhang et al., 2004). Previous studies from
our laboratory have documented the toxic effects of glutamate in cultured pig RGCs
that is mediated through NMDA receptors (Wehrwein et al., 2004). Additionally,
Brandt et al. (2011) observed increases of intracellular calcium during glutamateinduced cell death in cultured pig RGCs and linked this increase of calcium influx to
activation of apoptotic pathways.

Apoptosis

Apoptosis in glaucoma affects a wide range of neural cell types, particularly
RGCs, whose axons make up the optic nerve. Apoptosis occurs when a group of
enzymes are activated that cause the cell to degenerate (Kerr et al., 1972). This is
thought to be a built-in defense mechanism that allows cells to self-destruct when they
are introduced to abnormal environmental cues or to abnormal stimuli (Kerr et al.,
1972). Under chronic conditions, this may provide an adaptive advantage. Yet, in
acute or transient events, protection from these adverse environments may provide a
new approach to prevent cell death caused by over-stimulation of receptors in
neurodegenerative diseases, such as glaucoma. During apoptosis an increase of
calcium in the cell activates caspases from the mitochondria (Earnshaw et al., 1999;
Fesik, 2001). Cytochrome-c is then released from the mitochondrial matrix and
activates caspases to cleave intracellular proteins (Martinez-Caballero, 2005). Many
12

studies have demonstrated that loss of RGCs, in both human and animal models of
glaucoma, take place by apoptosis rather than by a non-specific trauma from
mechanical deformation resulting in IOP (Garcia-Valenzuela et al., 1995; Quigley,
1995; Pease et al., 2000; Brandt et al., 2011). Particularly, apoptosis has been shown
to occur after an elevated IOP (WoldeMussie et al., 2001; Levkovitch-Verbin et al.,
2002).
Previous studies from this laboratory investigated the possible mechanisms
during glutamate-induced cell death in cultured RGCs (Asomugha et al., 2010).
Results from these studies showed that there was an up-regulation of P38 mitogenactivated protein kinase (MAPK) that occurred in response to glutamate-induced cell
death. P38 MAPK was found to be associated with glutamate-induced apoptosis in
isolated pig RGCs (Asomugha et al., 2010).

Neuroprotection

Neuroprotection is a therapeutic strategy aimed at preventing or slowing the
neurodegenerative process. A variety of processes can lead to cell degeneration in
neurons including; increased levels of oxidative stress, mitochondrial dysfunction,
inflammatory changes, iron accumulation, protein aggregation, and as already
outlined, cell death caused by over-stimulation of receptors (Dunnet, 1999; Page et al,
1999; Agarwal et al, 2009; Seidl and Potashkin, 2011). Common neuroprotective
agents that have been used to prevent cell death caused by over-stimulation of
receptors have included; glutamate antagonists, neurotrophic factors, agonists and
antioxidants. These agents aim to limit cell death caused by over-stimulation of
13

receptors and oxidative stress, mediated through activation of respective receptors
(Agawal et al., 2009).
Previous studies from this laboratory have demonstrated the neuroprotective
effects of various nAChR agonists (Wehrwein et al., 2004; Thompson et al., 2006;
Asomugha et al., 2010; Brandt et al., 2011; Birkholz, 2011; Iwamoto 2011).
Asomugha et al. (2010) investigated the possible neuroprotective mechanisms in
glaucoma-like conditions using ACh as a neuroprotective agent in cultured pig RGCs.
Results from this study proposed two major pathways that could prevent loss of RGCs
associated with glutamate-induced cell death. One of these pathways, triggered by
pre-treatment of cultured RGCs with ACh, was the cell-survival phosphatidylinositol
3-kinase (PI3)-Akt pathway. Activation of this pathway enhanced cell survival against
glutamate-induced cell death. In addition, ACh pre-treatment of cultured RGCs also
resulted in inhibiting the apoptotic pathway by decreasing phosphorylated P38 MAPK
level (Asomugha et al., 2010). Additionally, calcium imaging studies conducted by
Brandt et al. (2011), suggested that calcium permeation through nAChRs was
responsible for activation the intracellular cascades engaged with neuroprotection.
The studies in this thesis focused on using an alpha7 nAChR agonist, PNU-282987, to
determine its neuroprotective effects in-vivo.

PNU-282987

PNU-282987

(N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide

hydrochloride) is a specific α7 nAChR agonist (Bodnar et al., 2005; Hajos et al.,
2005). This high specificity of PNU-282987 makes it a beneficial agonist for
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addressing neurodegenerative diseases such as glaucoma. PNU is an acronym for
Pharmacia and Upjohn, the company where this pharmaceutical was produced and
developed. Initially, this agonist was used as a treatment of schizophrenia, but proved
to be unsuitable for human use because of its excessive inhibition of hERG potassium
channels located in the heart (Walker et al., 2006). However, this agent may prove to
be a promising treatment for glaucoma if it is applied as eye drops, but only if eye
drop application does not reach the heart and affect cardiac physiology. In this study,
PNU-272987 was applied as eye drops in Long Evans rats that underwent hypertonic
saline injections to induce glaucoma to determine if PNU-282987 prevents
degeneration of RGCs. Liquid chromatography: mass spectroscopy with triple quad
capabilities (LC/MSMS) was also used to detected PNU-282987 in the retina, blood
plasma and heart tissue after eye drop application.

Previous Studies

Results from Iwamoto et al. (2013) demonstrated that the homomeric α7
nAChRs are present on rat RGCs. These findings encouraged us to determine if
activation of these receptors could provide neuroprotection against loss of RGCs
associated with glaucoma-like conditions in an in-vivo model of glaucoma in Long
Evans rats. Iwamoto (2011) first demonstrated the neuroprotective effects of the
specific α7 nAChR agonist, PNU-282987, in glaucoma-like conditions in-vivo. It was
observed that when PNU-282987 was administered as intravitreal injections, cell
death of RGCs in the rat retina was minimized in glaucoma-like conditions. An acute
model of glaucoma was generated in Long Evans rats using hypertonic saline
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injections as described in Morrison et al. (1997). The results from Iwamoto (2011)
and Iwamoto et al. (2013) support the hypothesis that the α7 nAChR agonist, PNU282987, has a neuroprotective effect in the rat retina under glaucoma-like conditions
when delivered as intravitreal injections in-vivo. We were encouraged about the
possible development of this compound to be used for therapeutic treatment of
glaucoma, although intravitreal injection is not a likely preferred route of
administration.
Previous studies in our laboratory have labeled cell bodies in the RGC layer
using cresyl violet (Birkholz, 2011; Iwamoto, 2011) before and after PNU-282987
treatment and the procedure to induce glaucoma-like conditions. However, labeling
cell bodies in the RGC layer using this method leads to inconclusive results
concerning the identity of the labeled cells as cells other than RGCs can be found in
the RGC layer.

Iwamoto (2011) therefore, used an antibody against Thy 1.1

glycoprotein to exclusively label RGCs and Thy 1.1 glycoprotein is only found on
RGCs in the retina.

This method revealed retinal changes associated with the

glaucoma-like condition that had not been previously characterized or examined.
To follow up on these studies, the neuroprotective effect of PNU-282987
against the loss of RGC under glaucoma-like conditions was repeated using a less
invasive delivery method. This thesis focused on the delivery of PNU-282987 as eye
drops to determine if neuroprotection against loss of RGCs under glaucoma-like
conditions could be achieved. In addition, this study was designed to detect levels of
PNU-282987 in the retina after eye drop application using LC/MSMS to determine if
PNU-282987 reaches the retina and remains in the eye after eye drop application.
LC/MSMS analysis was also conducted in the blood plasma and heart tissue after eye
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drop application to determine if PNU-282987 could be detected in these tissues.
Finally, general retinal morphometrics were analyzed in this study before and after
inducing glaucoma-like conditions. These retinal morphometric issues have not been
previously examined in our laboratory and provide an insight into how
experimentally-induced glaucoma manifests itself.
The neuroprotective characteristic of PNU-282987 in the retina opens up the
possibility for a new treatment for glaucoma that does not solely deal with reducing
IOP. Using these new neuroprotective methods in conjunction with already existing
treatments could potentially lead to preventative care in glaucoma. The results from
these experiments strengthen the hypothesis that activation of α7 nAChRs on rat
RGCs can prevent the loss of RGCs that occurs under glaucoma-like conditions.
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METHODS

Animals

Adult Long Evans rats (males and females between 3 and 6 months) were used
for all in-vivo studies. Rats were kept at Western Michigan University’s animal
facility until they were needed. Outbred Long Evans rats were used as a model strain
because visual deficits are not prominent in this strain (Jeffery et al., 1997), retinal
dissections are easily done against a pigmented background and their docile nature
allows them to be easily handled. A breeding colony of Long-Evan rats (Charles River
Labs, Portage, MI) was established. All animals were cared for in accordance with
the approved guidelines of the Institutional Animal Care and Use Committee
(IACUC) of Western Michigan University.

Inducing Glaucoma-Like Conditions

The procedure to induce glaucoma-like conditions in rats was modified from
the procedures initially described by Morrison et al., (1997). Figure 1 schematically
displays the organization of the hypertonic injection procedure. Long Evans rats were
anesthetized with 0.1ml/100ml KAX by intraperitoneal injections until no rat reflexes
were observed. KAX is a combination of 5 ml of ketamine (100 mg/ml), 2.5 ml
xylazine (20 mg/ml), 1 ml acepromazine (10 mg/ml), and 0.5 ml sterile water. A
topical anesthetic of 0.5% procaine hydrochloride was applied to the eye before the
hypertonic saline injections to induce glaucoma-like conditions. Once the animal had
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no signs of reflexes, a hemostat was used to pinch the eyelid, so the eye bulged out of
the eye socket, revealing the episcleral vein for injection of the hypertonic saline
solution (Figure 3C). The right eye was used for surgical manipulation while the left
eye served as a control for each experiment unless noted otherwise. The needle used
for injection was a long glass micro needle, 40 µm in diameter that was pulled from a
Narishige electrode puller (Figure 3B). The glass electrode was glued onto a tapered
polyethylene tubing (PE-50, Clay Adams, Parsippan, NJ) and inserted into a 23 gauge
needle with the tip filed off (Figure 3B). The glass needle was subsequently beveled
for easy penetration into the episcleral veins. An injection of 50 µl sterile 2 M
hypertonic saline was injected into the vein with sufficient pressure to cause
blanching of the episcleral veins. This causes scaring due to sclerosis of the
hypertonic saline in the trabecular meshwork and decreases aqueous outflow which,
in turn, slowly increases IOP (Johnson and Tomarev, 2011, Nissirios et al, 2009,
Morrison et al., 1997). Following the injection, the hemostat was released, antibiotic
cream was added to the region of the eyelid that was pinched and the rat was put back
in its cage until it fully recovered. The entire procedure was completed before the
animal woke and animals were closely watched to ensure full recovery before they
were returned to the animal facility.
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Episcleral veins

Figure 1
Schematic of hypertonic saline injection. The needle used for injection is a 3 mm long
glass micro needle, 30 µm in diameter (B), which is glued onto a tapered polyethylene
tubing, inserted into a 23 gauge needle with the tip filed off (A). The glass needle was
subsequently beveled for easy penetration into the episcleral veins. An injection of 50
µl sterile 2 M hypertonic saline was injected into the vein with sufficient pressure to
cause blanching of the episcleral veins (C). (Modified labeling from Linnb et al.,
2011)

Eye Drop Application

In-vitro studies previously demonstrated that ACh has a neuroprotective role
against glutamate-induced cell death in RGCs (Wehrwein et al., 2004; Thompson et
al., 2006) and that neuroprotection is mediated through α7 nAChR subunits
(Thompson et al., 2006). Therefore, to determine if the α7 nAChR agonist, PNU282987, has a neuroprotective effect under physiological conditions, the α7 nAChR
specific agonist was introduced by eye drops to Long Evans rats prior to the
procedure that induced glaucoma-like conditions. Four different concentrations of
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PNU-282987 were used to determine which concentration of PNU was the most
effective at preventing loss of RGCs. The four different concentrations chosen were at
10 times the concentration used in studies where PNU-282987 was injected
intravitreally (Iwamoto, 2011). The four different concentrations of PNU eye drops
used in this study were 100 µM, 500 µM, 1 mM, and 10 mM PNU-282987. The PNU
compound was dissolved in dimethyl sulfoxide (DMSO) to make a stock solution and
then diluted in PBS to allow transportation of PNU-282987 through the sclera to the
retina. The eye drops were applied for three days before the injection of hypertonic
solution designed generate glaucoma-like conditions. Following hypertonic saline
injections, eye drops were applied twice a day for one month. Eye drops were
delivered twice a day since LC/MSMS studies demonstrated that there was PNU282987 detected in the retina up to 12 hours after application (Linna et al., 2011).
Animals were sacrificed after one month since previous studies have demonstrated
that significant loss of RGCs occurs one month following hypertonic saline injections
in the periphery (Iwamoto, 2011). Application for longer periods could cause retinal
detachment from the effects of the hypertonic injection procedure (Morrison et al.,
1997). Rats remained in their cages as the eye drops were applied. After each eye
drop, the rats were given cheerios as a positive reinforcement. Eye drops were
delivered using separate plastic syringes for each dose and were aimed at the bulbar
conjunctiva, since that was the easiest access for the eye drops to seep into the interior
of the eye socket while also retaining consistency in the administration of PNU282987.
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Quantification of RGC Loss

After rats were exposed to PNU-282987 for a month, they were sacrificed and
retinas were removed from the eyes. Rats were euthanized in a carbon dioxide
chamber for 5 minutes to ensure the animal was deceased. After 5 minutes, the animal
was checked to ensure that there was no respiratory or reflex activity. The animals
had both left and right retinas surgically removed from the eyes after removal of the
cornea, lens and vitreous humor. Care was taken to peel the retina off the back of the
remaining eyecup in one piece to maintain anatomical landmarks. Whole retinas were
then flat mounted, pinned out in a sylgard dish with the RGC layer facing upward
using cactus needles, and fixed in 10% formalin overnight at 4° C. Figure 2 illustrates
an example of a retinal flat mount. After the samples were fixed, the tissue was rinsed
with PBS three times. To block nonspecific binding, the tissue was incubated in 2%
BSA in PBS containing 0.02% saponin for 30 minutes at room temperature before
applying the primary antibody. Thy 1.1 (BD Biosciences), is a monoclonal antibody
against glycoproteins only found in RGCs in the retina (mouse anti-rat) (Barnstable
and Drager, 1984). Preliminary serial dilution studies determined that optimal results
were obtained when the primary antibody was diluted 1:300 in 0.02% saponin in PBS
with 2% BSA for 1 week at 4o C in a humidified chamber. After a week, the primary
antibody was rinsed 3 times using PBS and incubated in fluorescent secondary
antibody (goat anti-mouse IgG), Alexa Fluor 595 (Invitrogen/Molecular Probes), for
visualization. After one week, the incubated tissue was rinsed and mounted on glass
slides using 50% PBS and 50% glycerol.
In control studies, experiments were conducted to determine specificity of
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the antibodies used.

Negative control experiments were performed to examine

antibody specificity. In some experiments designed to determine antibody specificity,
large RGCs were processed with the primary antibody omitted, while other
experiments substituted non-immune mouse immunoglobulin (dilution: 0.1 – 1.0
µg/ml) for the monoclonal antibody. In other experiments designed to determine
antibody specificity, preabsorption controls were performed where the primary
antibody and Thy 1.1 antigen were added together before applying to tissue. No
significant epifluorescence was observed under any of these conditions.
Glass slides with retinal tissue were visualized using a Zeiss confocal
microscope. Using the Z stack function of the confocal microscope, images were
obtained from the periphery of the retina 400 microns from the optic nerve head
(Figure 2). This measurement was based on previous studies showing that the greatest
amount of damage occurs in the periphery (Iwamoto, 2011).

Figure 2
Rat retina flat mount. Unlabeled rat retina flat mount visualized under compound light
on Zeiss confocal microscope with added frames 400µm from ONH. The yellow
squares indicate regions where cell counts were performed.
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Images were obtained throughout the entire RGC layer in 1 µm increments, to
properly account for RGC density. As the distribution of RGCs can be uneven in
different regions of the rat retina (Dreher et al., 1985), images were obtained from
four 80 µm2 spaces that surround the optic nerve head at 400 µm away from the
center of the optic nerve head (Figure 2). The total number of Thy 1.1 labeled RGCs
in each square 400 µm from the optic nerve head were counted in experimental and
control retinas. Counts were taken from similar anatomical landmarks in each eye
using Metamorph software.

RGC and axon fascicle counts were analyzed and

graphed using GraphPad software.
Quantification of RGCs was formulated using an 80 µm2 frame placed on
every retinal image that was taken. The position of this square was placed to avoid
axon fascicle interference 400 µm from the ONH. Preliminary studies used the 80 µm
square frame at multiple identified locations 400 µm from the ONH to take images,
count and average the number of RGCs. There were significant differences in RGC
counts if 2 or 3 squares were averaged 400 µm from the ONH. However, if 4, 6 or 8
squares were evenly distributed around the ONH 400 µm from the ONH, the average
RGC counts were significantly similar. As a result, 4 images were taken from each
retina and RGC counts were averaged in all studies.

LC/MSMS Analysis of Rat Retina, Blood Plasma and Heart Tissue

LC/MSMS (liquid chromatography: mass spectroscopy with triple quad
capabilities) was performed according to standard procedures on retina, plasma and
heart samples removed from sacrificed Long Evans rats at various time points
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following eye drop applications. Retinas, blood plasma and heart samples (atria and
ventricle) were removed from asphyxiated rats after different concentrations of PNU282987 was applied to rat eyes as eye drops for various amounts of time. Collected
samples were removed from experimental animals, weighed and placed on ice
immediately after removal and sent to the Michigan Innovation Center of Kalamazoo,
MI to perform LC/MSMS analysis for quantification of PNU-282987 in each sample.
Five samples were collected for each time and dose response experiment. Three
different concentrations of PNU-282987 was applied to rat eyes (100 µM, 1 mM and
10 mM) for five different amounts of time before the animals were sacrificed and
tissue was collected and put on ice. Animals were sacrificed 1, 2, 4, 8 and 12 hours
after eye drop application of PNU-282987. At the Innovation center, each sample
collected were labeled and placed in -80oC until processed for LC/MSMS analysis.
Preliminary studies using LC/MSMS detected PNU-282987 in rabbit retina when the
agent was applied as eye drops (Linnb et al, 2011). These studies were repeated using
the glaucoma rat model and performed on plasma and heart tissue in rat to examine
the idea that PNU-282987 can be detected in the retina when applied as eye drops, but
may not be detected in blood plasma or heart tissue.

LC/MSMS Sample Preparation

At the Michigan Innovation Center, the tissue was transferred to
homogenation tubes and appropriate volumes of saline were added to each tube to
make a tissue concentration of 50 mg/ml. Each retinal tissue was homogenized for
approximately 3 minutes using a pestle and homogenation tube (Kimble-Chase). A
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volume of homogenized rat tissue or plasma was combined with an equal amount of
blank avetonitrile and an equal amount of acetonitrile containing internal standard for
total volume of 1 ml. Standards were prepared by combining an aliquot of control
retinal tissue homogenate with calibration spiking solution in acetonitrile and internal
standard in acetonitrile. All samples were placed in a vortex to precipitate proteins
and then centrifuged for 10 minutes at 14,000 rpm at 4°C. Supernatants were
transferred to autosampler byls and dried in a SpeedVacand reconstituted in 0.1%
formic acid/10% acetonitrile for LC/MSMS.

LC/MSMS Analysis

LC/MSMS was performed on a Waters Quatro Micro triple quadruple mass
spectrometer using positive ion electrospray ionization. A Waters CapLC capillary
HPLC was configured for on-line SPE. Additional experimental details can be found
in Linnb et al., (2011).

Statistical Analysis

All cell counts were compared to the internal control counts for each trial.
Student T-tests were used for single comparisons. Statistical analysis was performed
on all normalized data using Kruskal-Wallis non-parametric analysis of variance
(ANOVA) with post hoc multiple comparisons (Dunn’s test). Two-way ANOVA with
correction for multiple comparisons was conducted on data that was not normalized.
P<0.05 was considered statistically significant for all tests.
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RESULTS

Inducing Glaucoma-Like Conditions Causes Loss of RGCs

The left eye in each experimental animal was left untreated to act as an
internal control and right eyes were manipulated with hypertonic injections to induce
glaucoma-like conditions. One month following injection of the hypertonic saline into
the episcleral vein of the right eye, animals were sacrificed, the retinas were removed
in one piece, flat-mounted onto sylgard dishes and the retinas were process for
visualization using an antibody against Thy 1.1 to label RGCs. An example of the
results obtained following this procedure is shown in Figure 3. Figure 3A illustrates
an image of labeled RGCs and labeled RGC axon fascicles that was obtained from the
control untreated eye of a Long Evans rat 400 µm from the ONH.

Figure 3B

illustrates an image from a similar retinal location, from the same rat, but in the right
eye, which underwent a procedure to generate a glaucoma model. Rats injected with
hypertonic saline experienced a noticeable RGC count loss compared to the internal
control.
It was observed from RGC labeling experiments that hypertonic saline
injections had different effects in the retina. Panels shown in Figure 3A and 3B, show
the results when the left eye was not manipulated and the right eye underwent
hypertonic saline injections. Panel 3A shows RGCs (arrow heads) and main axon
fascicles (double-headed arrows). Defasciculation off the main axon fascicles was
also observed (single arrows). Panel 3B also shows labeled RGCs (arrow heads) and
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main axon fascicles (double-headed arrows). Defasciculation off the main axon
fascicles was also observed (single arrows), and was more prominent than compared
to the internal control. It was also observed that the main axon fascicle diameter was
altered when compared to the internal control.

Right Eye

Control

Hypertonic Injection

Left Eye

Figure 3
Injection of hypertonic saline. (A) Left eye: untreated internal control with labeled
RGCs using antibody against Thy1.1 in grayscale. (B) Right eye: glaucomatous retina
one month following injection of 50 µl hypertonic saline. Scale represents 50 μm.
The images were obtained from the same animal. Arrow heads indicate labeled RGCs.
The double arrow indicates axon fascicles.

The bar graph in Figure 4 summarizes the effects of hypertonic injections on
RGC loss compared to control untreated conditions. Rats eyes injected with
hypertonic saline experienced a significant decrease in cell counts of 26% (±2.19;
N=9) when normalized to internal controls. Studies to analyze morphological
differences in the retina are discussed later in this thesis
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Figure 4
RGC counts compared in control and hypertonic saline injected retinas. Bar graph
represents the normalized average RGCs in the right eye (red bar) compared to the left
internal control (black bar) (N=9). Hypertonic saline injection to the episcleral vein
significantly decreased RGC counts when compared to internal control. Error bars
represent SEM. *represents significance to internal control.

Dose-dependent Response of PNU-282987

The images shown in Figure 5A and Figure 5B illustrate the effect of
hypertonic saline injections to induce glaucoma-like conditions in a Long Evans rat
that was already shown in Figure 3.

To determine if PNU-282987 had any

neuroprotective effects when applied as eye drops, left control and right experimental
retinas were removed from animals after treatment of using PNU-282987 as described
in Materials and Methods. It was observed from RGC labeling experiments that each
dose of PNU-282987 had different effects in glaucoma-like conditions. Panels shown
in Figure 5C and 5D, show the results when the right eye of another animal was
treated with 100 µM PNU-282987 under glaucoma-like conditions (Figure 5D) and
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the left eye was left untreated (Figure 5C). These images were obtained from the same
animal. Panel 5C shows RGCs (arrow heads) and main axon fascicles (double-headed
arrows). Defasciculation off the main axon fascicles was also observed (single
arrows). Panel 5D also illustrates labeled RGCs (arrow heads) and main axon
fascicles (double-headed arrows) under glaucoma-like conditions, with the treatment
of 100 µM PNU-282987. Defasciculation off the main axon fascicles was also
observed (single arrows), and was more prominent than compared to the internal
control. It was also observed that the main axon fascicle diameter was reduced when
compared to the internal control, similar to results shown in Panel 5B. There was also
apparent RGC loss in the right eye even when treated with 100 µM PNU-282987
when compared to the left internal control. RGC morphology was also altered in the
right eye having a blebbed membrane appearance that was not observed in the left
internal control. In summary, 100 µM PNU-282987 did not act to protect against
changes associated with a procedure to generate glaucoma-like conditions.
Panels 5E and 5F, illustrate the result when the right eye was treated with 500
µM PNU-282987 under glaucoma-like conditions. Both images in the panels were
obtained from the same animal. Panel 5E illustrates RGCs and main axon fascicles
with defasciculation. Panel 5F illustrates RGCs and main axon fascicles under
glaucoma-like conditions with the treatment of 500 µM PNU-282987. Although there
was still some defasciculation off the main axon fascicles, reduced diameter in the
main axon fascicles and decreased RGC counts compared to the internal control, 500
µM PNU-282987 had measurable neuroprotective effects. The neuroprotective effect
of PNU-282987 increased in the presence of 1 mM PNU-282987. When the retina
was treated with 1 mM PNU 282987, there was less defasciculation, the diameter of
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the main axon fascicles appeared similar to the diameters in the control retina and
RGC densities in 1 mM PNU treated retinas were similar to RGC densities in the
untreated control retina (Figure 5G and 5H).
A substantial degree of neuroprotection was evident when eyes were treated
with 10 mM PNU-282987 (Figure 5I and 5J).

Little to no defasciculation off the

main axon fascicles was observed in the experimental eye (Figure 5J). When treated
with 10 mM PNU-282987, the diameters of the main axon fascicles were similar in
comparison to the control panels (Figure 5I). Finally, when treated with 10 mM PNU
282987, the RGC profiles were smooth and RGC density was similar to internal
control counts.

31

Right Eye

500 µM
10 mM

Control

1 mM

Control

100 µM

Control

Control

Control

Hypertonic Injection

Left Eye

Figure 5
Treatment of RGCs using different concentrations of PNU-282987. Samples of
images obtained from RGCs in rat retina labeled with fluorescently tagged antibody
against Thy 1.1 in grayscale. Images in the left column represent control untreated
images for the experimental images shown in the right column. Images were obtained
1 month following procedure to induce glaucoma-like conditions from the same
animals in each row. (B) Labeled RGCs after eyes were injected with hypertonic
saline injections. (D) Labeled RGCs after treatment of 100 μM PNU-282987 before
and after procedure to induce glaucoma-like conditions. (F) Labeled RGCs after
treatment of 500 μM PNU-282987 before and after procedure to induce glaucoma-like
conditions.. (H) Labeled RGCs after treatment of 1 mM PNU-282987 before and after
procedure to induce glaucoma-like conditions. (J) Labeled RGCs after treatment of 10
mM PNU-282987 before and after procedure to induce glaucoma-like conditions. The
images in each row were obtained from the same animal and from the anatomical
location. Arrow heads indicate labeled RGCs. The double arrow indicates axon
fascicles. Single arrows indicate defasciculation. Scale bar is 50 μm.
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From the fluorescent imaging shown above, it was apparent that RGC loss was
minimized when eyes were treated with the higher doses of PNU-282987. The
summarized results of these dose-response studies are shown in Figure 6. One month
following induction of glaucoma-like conditions, there was an average of 26% (±
2.19, N=9) loss of RGCs. Eye drop application of PNU-282987 before and after
hypertonic injection resulted in prevention of RGC loss in a dose-dependent manner.
Application of 100 µM PNU-282987 had no significant effect on RGC loss associated
with the procedure to generate a glaucoma model. This was indicated with a 22.3% (±
5.81, N=5) RGC loss in the right eye treated with 100 µM PNU-282987 when
compared to the left internal control. However, when 500 µM PNU-282987 was
applied, 8.4% (± 3.8, N=3) of RGCs were lost compared to the internal untreated
controls. This result was found to be significantly different from internal control
conditions. When 1 mM PNU-282987 was applied, only 6.9% (± 3.84, N=5) of RGCs
were lost compared to untreated controls and represents statistically significant
neuroprotection from eyes treated with hypertonic injections. Protection of RGCs also
occurred when 10 mM PNU-282987 eye drops were applied to manipulated eyes.
When treated with 10 mM PNU-282987, RGC percentage increased by an average of
13.5% (± 4.19, N=5) compared to the untreated controls.
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Figure 6
Summary of results following eye drop treatment of PNU-282987 before and after
hypertonic injections. Each bar graph represents the normalized average change of
RGCs compared to control untreated conditions that were measured 1 month
following procedure to induce glaucoma. Treatment of 100 μM PNU-282987 (N=5),
500 μM PNU-282987 (N=3), 1 mM PNU-282987 (N=5), and 10 mM PNU-282987
(N=5) are shown. Eye drop application of PNU-282987 before and after hypertonic
injections resulted in prevention of RGC loss in a dose dependent manner. Error bars
represent SEM. *represents significant different from the glaucoma-induced results
(dark grey bar).

Morphological Differences

Morphological changes occurred in the rat retina as a result of injecting
hypertonic solution into the episcleral vein of the right eye, as demonstrated in earlier
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experiments. These morphological changes were not previously described in our
laboratory. By using a new marker to label RGCs, retinal changes could be analyzed
that were previously obscure. These morphological changes in the retina decreased or
diminished as higher doses of PNU-282987 were administered. Hypertonic injections
with no treatment of PNU-282987 had the most visible changes on retinal
organization. In comparison, using 10 mM PNU-282987 on retinal tissue before the
procedure to induce glaucoma-like conditions had little or no changes on retinal
arrangement, demonstrating a similar appearance to the internal control. The method
of labeling RGCs using an antibody against Thy 1.1 opened up the opportunity to
examine the anatomical changes in the retina during glaucoma-like conditions. In this
thesis, 3 different morphological changes in the RGC layer were analyzed with and
without PNU-282987 treatment to the eye.

These morphological changes are

discussed in the following sections.
Figure 5 (A, C, E, G, and I) displays images illustrating typical retinal
arrangement and organization. These images were obtained from untreated eyes
where RGCs and axons were labeled with the antibody against Thy 1.1. In control
conditions, there are thick axon fascicles (double arrows), and little to no
defasciculation off the main axon fascicles (tissue strands less than 2 µm). The
morphology of the membrane in the RGCs typically has a smooth round appearance
(arrow heads), and the vast majority (90%) of the image is covered with labeled
RGCs. However, after the procedure to induce glaucoma-like conditions, significant
differences in retinal arrangement and morphology occurred. The first morphological
differences being discussed are changes in main axon fascicle diameter.
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Main Axon Fascicle Diameter

When the retina was stained with antibody against Thy 1.1, the retina was
layered in thick axon fascicles leading to the ONH as shown by the double arrows
illustrated in Figure 5 (A, C, E, G, and I). If RGCs were lost after hypertonic injection,
it was expected that the diameter of the axon fascicles carrying the axons of those
RGCs would also change. To determine if the diameters of main axon fascicles
changed with different manipulations, the thickest section of each fascicle in each
image was measured, an averaged diameter was computed and the average was
compared to the average diameter of main axon fascicles obtained under control
untreated conditions 400 µm from the ONH. Measurements were taken from the
widest part of all main axon fascicles from each image and analyzed. If the main axon
fascicle branched into different axon fascicles, the axons were excluded from
measurements and only the main axon fascicle was measured. Manipulated right eye
measurements were compared to the left internal controls. There were two scenarios
that compared differences in main axon fascicle diameter between left untreated
controls and right experimental eyes. The first scenario included experiments where
the right eye was only given injections of hypertonic saline. The second scenario
included experiments where the right eye was given injections with hypertonic saline
along with treatment with 10 mM PNU-282987.
Figure 7 illustrates the results obtained when the left internal control eyes were
compared to the right eyes that only had hypertonic injections to induce glaucomalike conditions. When manipulations were performed to generate a glaucoma model,
the average axon fascicle diameter measured from the left untreated control retinas
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was 15.7 µm (± 0.57, N=6). The average main axon fascicle diameter from right
experimental eyes was 12.1 µm (± 0.86, N=6). The injections to induce glaucoma
significantly decreased the main axon fascicle diameters when compared to the
internal control. Thus, there was an average decrease in axon fascicle diameter of
25% (± 0.25, N=3) compared to the left internal control.
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Figure 7
Axon fascicle diameter comparison between control and hypertonic saline injected
retinas. The graph represents the normalized average axon fascicle diameter 1 month
following procedure to induce glaucoma-like conditions in the right eye. Left internal
control eyes were not manipulated in any way (black bar) and the right eyes were
subjected to injection of hypertonic solution (red bar) to induce glaucoma-like
conditions with no treatment of PNU-282987. Measurements were taken from the
thickest diameter of the axon fascicles 400 µm from the ONH (N=6). Error bars
represent SEM. *represents significance to internal control.

If retinas were treated with 10 mM PNU-282987 before and after hypertonic
injections and for a month following hypertonic saline injections, the main axon
fascicle diameter in the left internal controls averaged 20.1 µm (± 1.16, N=5). When
the right eyes were treated with 10 mM PNU-282987 before and after hypertonic
injections resulted in an average diameter of 19.2 µm (± 1.03, N=5). Results of these
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experiments are summarized in Figure 8. When the experimental axon fascicle
diameter was compared to the left internal control fascicle diameter, measurements
only decreased by an average of 4.8% (± 9.06, N=5) and were not significantly
different from each other.

% Axon Fascicle Diameter

No Surgery vs Surgery and 10 mM PNU
100

50

0
Control

Surgery and
10mM PNU Treatment

Figure 8
Axon fascicle diameter comparison between control and retinas with hypertonic
injections and 10 mM PNU-282987 treatment. The graph represents the normalized
average axon fascicle diameter 1 month following procedure to induce glaucoma in
the right eye. Left internal control eyes were not manipulated in any way (black bar)
and the right eyes were subject to hypertonic injections to induce glaucoma-like
conditions and treatment with 10 mM PNU-282987 (N=5) (yellow bar). Error bars
represent SEM.

The following control study was performed to determine if main axon fascicle
diameter changed from the internal control using nothing but 10 mM PNU-282987
treatment. This control experiment was conducted to determine if PNU-282987
treatment would cause any unprecedented effects. When right eyes were treated with
10 mM PNU-282987 without an injection of hypertonic solution, there were no
visible morphological differences. Specifically there were no changes in axon
diameters and there was no noticeable change in the smoothness or shape of the RGCs
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between control and PNU-282987 treated retinas. An example of this is shown in
Figure 9A and 9B.

Right Eye

10 mM*

Control

Left Eye

Figure 9
Treatment with 10 mM PNU-282987 without a hypertonic injection. (A) Untreated
internal control with labeled RGCs using antibody against Thy1.1 in grayscale. (B)
(*) Retina following treatment of PNU-282987 for one month. The images were
obtained from the same animal, in similar anatomical locations 400 µm from the
ONH. Arrow heads indicate labeled RGCs and double arrow indicates main axon
fascicles. Scale bar indicates 50 μm.

Under these experimental conditions, it was observed that there was an
average axon fascicle diameter of 21 µm (± 1.31, N=3) in control untreated retinas.
The right experimental eye with treatment of 10 mM PNU-282987 was observed to
have an average axon fascicle diameter of 20 µm (± 1.06, N=3). The summary of
these control experiments is represented in Figure 10. The bar graphs in Figure 10
demonstrate that there was an average difference in axon fascicle diameter of 5.3% (±
7.86, N=3) between the two conditions. No significant differences in axon fascicle
diameter were observed.
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Figure 10
Axon fascicle diameter comparison between control untreated retinas and retinas
treated with 10 mM PNU-282987 without hypertonic injections. The bar graph
represents the normalized average axon fascicle diameter in conditions that were
measured after the right eye was treated with 10 mM PNU-282987 for 1 month. The
control eyes were not manipulated in any way (black bar) and the right eye was
subject to only treatment of 10 mM PNU-282987 with no injection of hypertonic
solution (blue bar). This shows that 10 mM PNU-282987 by itself has no significant
effect on axon fascicle diameter size when compared to internal control (N=3). Error
bars represent SEM.

A summary of axon fascicle diameter results from all three experiments is
shown in Figure 11. Hypertonic saline injections designed to generate glaucoma-like
conditions significantly decreased axon fascicle diameter size when compared to
internal controls. However, hypertonic injections in conjunction with 10 mM PNU282987 failed to produce a significant effect on axon fascicle diameter. Finally, 10
mM PNU-282987 treatment alone did not affect axon fascicle diameter.
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Figure 11
Axon fascicle diameter comparison between four different conditions. Each bar graph
represents the normalized average axon fascicle diameter under various conditions.
(A) Average axon fascicle diameter size from internal controls of all trials (N=14). (B)
Right eye injected with hypertonic solution with no PNU-282987 treatment (N=6).
(C) Right eye injected with hypertonic solution and treated with 10 mM PNU-282987
(N=5). (D) Right eye with no hypertonic solution and treated with 10 mM PNU282987 (N=3). Error bars represent SEM. *represents significance to internal control.

Defasciculation Off Main Axon Fascicles

Another morphological difference that was examined in this thesis was in
regard to the defasciculation that occurred from the main axon fascicles. If main axon
fascicle diameter decreased after hypertonic injection, it could be solely the result of
RGC death and axon loss. Alternatively, one might expect the fascicle to defasciculate
into less tightly woven bundles as it dissociates. This would suggest additional,
unforeseen events in the progressive changes seen with cell death in the retina. This
experiment was to determine if there is any difference in defasciculation behavior
under different experimental conditions. The total number of defascicualted axons
from main axon fascicles was analyzed to determine if defasciculation of axons off
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the main axon fascicles increased after procedures to induce glaucoma-like
conditions. Defascicualted fascicles were defined as fibers extending from the main
axon fascicles in an 80 µm2 image obtained 400 µm from the ONH with a diameter no
larger than 2 µm.

A continuous filament was counted as 1 count. If a fascicle

branched into more filaments, each defasciculated branch was counted individually if
each branch measured less than 2 µm in diameter. Three different scenarios were
analyzed for defasciculation. In the first scenario, the number of fascicles from left
internal control images was compared to the fascicles counted from the right eye
where hypertonic injections were delivered to induce glaucoma-like conditions. In the
second scenario, defasciculation from left internal control images were compared to
the amount of defasciculation from right eyes that were subject to hypertonic
injections and 10 mM PNU-282987 treatment. Finally, the third comparison was
made between defasciculation occurring in left internal control images and right eye
images obtained after 10 mM PNU-282987 application. Images showing
defasciculated axons off the main fascicles are displayed in Figure 12B.
Panels A, C and E in Figure 12 shows left internal control images obtained
from each animal in each of the experimental scenarios. Left internal controls showed
minimal or no defasciculation occurring from the main axon fascicles. Figure 12B
illustrates the right eye treated with only hypertonic saline injections with no
treatment of 10 mM PNU-282987. The main axon fascicle diameter was decreased
and defasciculation off the main axon fascicle was higher compared to its internal
control. Figure 12D shows a right eye with glaucoma-like conditions by hypertonic
injections and treatment with 10 mM PNU-282987. Main axon fascicle diameter
appeared unaffected compared to the internal control and there was no defasciculation
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occurring from the main axon fascicles. Finally, Figure 12F illustrates an eye treated
with 10 mM PNU-282987 with no hypertonic saline injections. Similar to results in
Figure 12D, there were little or no changes in axon fascicle diameter and no prevalent
defasciculation when compared to its internal control.
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Figure 12
Defasciculation off main axon fascicles in different conditions. (A, C, and E) Left eye
images obtained from each animal that acted as untreated internal controls illustrating
labeled RGCs using antibody against Thy1.1 in grayscale. The images obtained in the
left columns correspond to the right images in each row from the same animals (B)
Image shows a right eye image obtained when the eye was injected with hypertonic
saline with no PNU-282987 treatment. (D) Right eye image obtained after hypertonic
injections and treatment with 10 mM PNU-282987. (F) (*) Right eye image obtained
from an eye only treated with 10 mM PNU-282987 with no hypertonic saline
injections. All images were taken after one month after hypertonic injections or
treatment to the right eyes 400 µm away from the ONH. Scale bar indicates 50 μm.
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The number of defasciculated axons counted under each condition is
summarized in Figure 13. For the first manipulation, the left control eye averaged
2.43 (± 0.81, N=6) fascicles, while the manipulated right eye that averaged 5.23 (±
0.4, N=6) fascicles (Figure 13). This was found to be statistically significant
compared to the internal control. Figure 13 summarizes the results obtained when the
number of fascicles from untreated controls was compared to manipulated right eyes
that had undergone 10 mM PNU-282987 treatment. Under these conditions, the left
control eye had an average of 3.42 (± 1.36, N=5) fascicles and the right eye averaged
2.82 (± 1.06, N=5) fascicles (Figure 13). This does not represent a significant
difference. Finally, Figure 13 summarizes the results obtained when comparing the
left control eye to right eyes that were treated with 10 mM PNU-282987. Under these
conditions, the left eye images obtained from 3 different animals averaged 3.0 (± 0.3,
N=3) fascicles off the main axon fascicles while the right experimental eyes averaged
3.77 (± 1.37, N=3) fascicles. Defasciculation observed in this study was shown to
increase from control untreated conditions after the procedure to induce glaucomalike conditions, but not if 10 mM PNU-282987 was applied.

44

Summary of Axon Defasciculation

# of Defasciculated Axons

6

*

4

2

0

A

B

C

D

Figure 13
Axon defasciculation off main axon fascicles in comparison between three different
conditions. Each bar graph represents the average number of defasciculated axons
from main axon fascicles in conditions that were measured 1 month following
procedure to induce glaucoma-like conditions. Control eyes were not manipulated in
any way and the right eyes were subject to manipulations. (A) Average defasciculation
in internal control for all three manipulations (N=14). (B) Right eye injected with
hypertonic solution with no 10 mM PNU-282987 treatment (N=6). (C) Right eye
injected with hypertonic solution and treated with 10 mM PNU-282987 (N=5). (D)
Right eye with no hypertonic solution and treated with 10 mM PNU-282987(N=3).
Error bars represent SEM. *represents significant different from internal control.
Retinal Ganglion Cell Morphology

Other than differences in axon fascicle diameter and defasciculation,
noticeable differences in RGC morphology were also observed under different
conditions. These morphological differences were observed when; hypertonic saline
was injected into the episcleral vein (Figure 5B); 100 µM PNU-282987 was
administered before and after glaucoma-like conditions; when PBS eye drops that
were substituted instead of PNU-282987 during glaucoma-like conditions (Figure
18B) and injection hypertonic saline to the episcleral vein of the left eye (Figure 16A)
when compared to their respective internal controls. It was observed in fluorescent
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labeling experiments that under these conditions RGCs had a distinct morphology
when compared to control and 10 mM PNU-282987 treated conditions such as those
illustrated in Figure 5. In control and PNU-282987 treated conditions the RGC
somata membrane was uniform with a smooth outline. Morphology of RGCs during
glaucoma-like conditions was blebbed and not circularly uniform. Using Image J
imaging and analysis software, quantification of this morphology was conducted. This
program uses an index that determines a value for circularity in cells. A circularity
value of 1.0 indicates a perfect circle. As the value approaches 0.0, it indicates
polygonal characteristics maximally debyted from perfect circular geometry. Using
Image J, the circumference from 3 different animals in both eyes was examined and
obtained a circularity index for RGCs. This was repeated in different scenarios and
compared to the left internal control. Circularity of RGCs was quantified in three
different scenarios leaving left eyes as untreated internal controls. The first scenario
had hypertonic saline injected to the right eyes to induce glaucoma-like conditions.
The second had hypertonic saline injections with 10 mM PNU-282987 treatment.
Finally, the third scenario had no hypertonic saline injections, only 10 mM PNU282987 treatment.
Quantification of circularity in RGCs demonstrated that RGCs in eyes
changed their circularity index under different conditions. In eyes that had hypertonic
injections the circularity index for RGCs was 0.63 (± 0.02, N=3). This circularity
index was significant when compared to the circularity index of 0.86 (± 0.01, N=3) in
internal controls. The circularity index for eyes that had 10 mM PNU-282987
treatment with hypertonic injections resulted in a circularity index of 0.89 (± 0.01,
N=3) and was not significant when compared to its internal control index of 0.89 (±
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0.01, N=3). The circularity index was also not significant in eyes that had 10 mM
PNU-282987 treatment without hypertonic injections. Right eyes had a circularity
index of 0.90 (± 0.06, N=3) when compared to the internal control index of 0.90 (±
0.01, N=3). Results summarizing these results are shown in Figure 14.
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Figure 14
RGC circularity index in comparison between three different conditions. Each bar
graph represents the average RGC circularity index in conditions that were measured
1 month following procedure to induce glaucoma-like conditions. Control eyes were
not manipulated in any way and the right eye was subject to manipulations. (A)
Average RGC circularity index in internal control for all three manipulations (N=9).
(B) Right eye injected with hypertonic solution with no 10 mM PNU-282987
treatment (N=3). (C) Right eye injected with hypertonic solution and treated with 10
mM PNU-282987 (N=3). (D) Right eye with no hypertonic solution and treated with
10 mM PNU-282987(N=3). Error bars represent SEM. *represents significant
different from internal control.

In addition to quantification of RGC membrane morphology, RGC somata size
was also examined. This analysis was conducted to determine if this change in
morphology altered RGC some size. I wanted to investigate the effects that the
hypertonic saline injection and treatment of 10 mM PNU-282987 had on the diameter
of individual RGC somata. The observation being tested in this study was that the
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injection of hypertonic saline and application of 10 mM PNU-282987 could affect the
size of RGC somata that survive after hypertonic saline injections and PNU-282987
treatment. Three different sets of experiments were analyzed in these studies. In the
first scenario, the diameter of RGC somata were measured in left control conditions
and compared to the diameter of RGC somata from the right eye manipulated
conditions. In the next condition, the diameter of RGC somata in left control eyes
were compared to the diameter of RGC somata that had the procedure to induce
glaucoma-like conditions and were treated with 10 mM PNU-282987. Lastly, the
diameter from the left internal control RGC somata were compared to the diameters
of right experimental RGC somata that were treated only with 10 mM PNU-2829897.
Measurements were obtained by taking a vertical and a horizontal measurement from
each cell, then adding the two distances together and computing the average.
Incomplete cells that did not show the complete circumference of the cell were
excluded from quantification. RGCs were considered small when their diameter was
less than 15µm and large RGCs were characterized as RGCs with diameter greater
than 15 µm.
Results illustrated in Figure 15 show that when the right eye was treated with
hypertonic injections to induce glaucoma-like conditions, an average diameter of 10
µm (± 0.01, N=4) was measured for small RGCs compared to an average diameter of
9.02 µm (± 0.41, N=4) in the control untreated eye in small RGCs. There was also no
significant difference in the diameter of small RGCs when eyes were treated with 10
mM PNU-282987 treatment before the procedure to induce glaucoma-like conditions.
An average diameter of 10 µm (± 0.026, N=4) was measured in small RGCs under
these conditions. Finally, when the retina was treated with just 10 mM PNU 282987,
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the average diameter of the small RGCs equaled 9.25 µm (± 0.25, N=4). None of
these averages were significantly different from any other diameter measurement
obtained from small RGCs and suggest that the RGC somata size does not
significantly change after surgical or pharmacological treatment with PNU-282987.
Similar results were obtained when the somata diameter of large RGCs were
measured. When large RGCs were analyzed, the average somata diameter measured
16.7 µm (± 0.29, N=4) under control untreated conditions and 17.5 µm (± 0.36, N=4)
for eyes that underwent the procedure to induce glaucoma-like conditions. When eyes
were surgically manipulated to induce glaucoma-like conditions but were treated with
10 mM PNU-282987, the average somata size for large RGCs equaled 18.75 µm (±
0.48, N=4). Finally, when retinas were treated with 10 mM PNU-282987 alone, the
average RGC somata diameter equaled 17.75 µm (± 1.11, N=4). There was no
significant difference detected in somata size that was associated with any treatments.
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Figure 15
Individual histograms of small RGC diameter. Histogram represents the distribution
in RGC somata size for small RGCs under 3 experimental conditions that were
measured 1 month following procedure to induce glaucoma. Left control eyes (black
bars) were not manipulated in any way and the right eye was subject to manipulations.
(A) Left internal controls distributed with right experimental conditions with
hypertonic injections and no treatment of 10 mM PNU-282987 (N=4) (red bars). (B)
Left eye subject to hypertonic injections with no PNU-282987 treatment and right eye
injected with hypertonic solution with 10 mM PNU-282987 treatment (N=4)(yellow
bars). (C) Left internal control compared to the right eye with no hypertonic injection
and only treated with 10 mM PNU-282987 (N=4) (blue bars).

Hypertonic Injections in both Eyes and PNU-282987 Treatment

In control studies, both eyes were subject to hypertonic injections to induce
glaucoma-like conditions, while the right eye was also treated with 10 mM PNU282987 eye drops. Results from fluorescent labeling experiments demonstrate that
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there was a significant difference in RGC survival when retinas were treated with 10
mM PNU-282987. The left eye had a disorganized appearance, apparent decrease in
RGC density and increased axon defasciculation when compared to the right eye
treated with 10 mM PNU-282987 (Figure 16A and 16B).

Right Eye
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Hypertonic Injection

Left Eye

Figure 16
Hypertonic injections in both eyes with 10 mM PNU-282987 treatment on the right
eye. (A) Left eye subject to hypertonic injections labeled with antibody against
Thy1.1 in grayscale. (B) Retina following treatment of 10 mM PNU-282987 for one
month following hypertonic injection. Arrow heads point to RGCs. Double arrow
indicates the axon fascicles. The images were obtained from the same animal 1 month
after hypertonic saline injections, from the same region of the retina 400 µm from the
ONH. Scale bar indicates 50 μm.

Results from this experiment illustrated a 20% (± 4.1, N=3) average increase
in RGC density in the right eye treated with 10 mM PNU-282987 when compared to
the left, glaucomatous, untreated eye. This result was shown to be significant when
compared to the left eye condition. Figure 17 summarizes the differences in cell
density between the right and left eye.
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Figure 17
Hypertonic injections in both eyes with 10 mM PNU-282987 treatment in the right
eye. The bar graph displays the normalized RGC change from the internal control.
Internal control subject to hypertonic injections (red bar) (N=3). Retina following
treatment of 10 mM PNU-282987 for one month with hypertonic injection (yellow
bar) (N=3). Error bars represent SEM. *represents significance to internal control

Hypertonic Injections with PBS Treatment

To verify that the neuroprotective effects seen in this study were due to PNU282987 and not the vehicle that the PNU-828987 was dissolved in; experiments were
conducted using PBS drops instead of PNU-282987. The left eye of several rats was
left as an untreated control and the right eye was subject to hypertonic injection to
generate glaucoma-like conditions. PBS treatment was administered 3 days before
hypertonic injections and for one month following hypertonic injections. Results from
these experiments illustrated a significant difference between the two images due to
the effects of the hypertonic injection (Figure 18A and 18B). Cell density was
noticeably reduced in experimental eye with PBS drops and hypertonic saline
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injections. There were similar morphological effects as those shown previously with
only hypertonic injections. The axon fascicles were reduced in diameter and RGC
density was also reduced. Defasciculation was also observed in eyes treated with PBS
under glaucoma-like conditions. RGCs also had a prominent blebbed appearance in
the plasma membrane. There was no clear neuroprotective effect of PBS when
combined with hypertonic injections.
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Figure 18
Hypertonic injections with PBS treatment in the right eye. (A) Untreated internal
control with labeled RGCs using antibody against Thy1.1 in grayscale. (B) Retina
following treatment of PBS drops for one month with hypertonic injection. Arrow
heads point to RGCs. Double arrow indicates the axon fascicles. The images were
obtained from the same animal. Scale bar represents 50 µm

The summary of these results is shown in Figure 19.

There was an overall

average decrease of RGCs by 16% (± 7.35, N=6) in the right experimental eye
compared to the internal control (Figure 19). This result was significant when
compared to the left internal control.
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Figure 19
Hypertonic injections with PBS treatment. The bar graph displays the normalized
RGC change from the internal control. Untreated internal control (black bar) (N=6).
Retina following treatment of PBS drops for one month after hypertonic injection
(grey bar) (N=6). The images were obtained from the same animal. Error bars
represent SEM. *represents significance to the left eye.

Treatment of PNU-282987 with no Hypertonic Injections

To verify that PNU-282987 has no effect on the RGC counts by itself, 10 mM
PNU-282987 was applied to the right eye with no hypertonic injections. Results were
compared to the left untreated internal control and differences were recorded after one
month of treatment. Results from fluorescent labeling experiments display similar
appearance in both eyes. There are no apparent morphological differences in both
eyes. Axon fascicles are organized and thick while RGCs are smooth in appearance.
Cell densities were also similar in both control and 10 mM PNU-282987 treated
retinas from the same animal. Figure 9 earlier in this study shows an example of the
fluorescent labeling results.
These results are summarized in Figure 20. When the right eye was only
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treated with 10 mM PNU-282987 drops, RGC counts were not significantly different,
main axon fascicle diameter were not visibly different and there was no increase of
axon defasciculation. The RGC counts between the right and left eyes under these
conditions demonstrated an average difference of 5.3% (± 6.9, N=4) (Figure 20),
which does not represent a significant difference in RGC counts between the two
eyes.
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Figure 20
Comparison with no hypertonic injections with 10 mM PNU-282987 treatment in the
right eye. Untreated internal control with labeled RGCs using antibody against Thy1.1
in grayscale (black bar) (N=4). Retina following treatment of 10 mM PNU-282987
drops for one month without hypertonic injection (blue bar) (N=4).Error bars
represent SEM.

Hypertonic Injection with no Primary Antibody

To verify that our primary antibody Thy 1.1, is labeling the glycoprotein in
RGCs, fluorescent labeling experiments omitting the primary antibody were
conducted in a subset of rats. In Figure 21A, the left control eye was processed
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normally for RGC staining. The right experimental eye underwent the procedure to
induce glaucoma-like conditions while being treated with 10 mM PNU-282987 for 1
month. After one month, retinas were processed for RGC staining with (Figure 21A)
and without (Figure 21B) using the monoclonal Thy 1.1 primary antibody. PBS was
substituted for the primary antibody in these instances. Without the primary antibody,
no fluorescence is observed (Figure 21B).
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Figure 21
RGCs labeled with Thy 1.1 primary antibody Left internal control fluorescently
labeled with thy 1.1 and right eye omitting thy 1.1 primary antibody in grayscale. (A)
Untreated internal control with labeled RGCs using the Thy 1.1 primary antibody. (B)
Retina following treatment of PNU-282987 after one month with hypertonic injection
with no primary antibody. The images were obtained from the same animal. Scale bar
indicates 50 μm.

LC/MSMS

The next experiments were designed to verify that PNU-282987 reached the
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retina when it was applied as eye drops, and to demonstrate that PNU-282987 could
not be detected in heart tissue after eye drop application. LC/MSMS was performed
on retina, plasma and heart samples removed from sacrificed Long Evans rats at
various time points following eye drop applications using three different
concentrations of PNU-282987. Specifically, retinas were removed from euthanized
Long Evans rats 1, 2, 4, 8 and 12 hours after applying 100 µM, 1 mM or 10 mM
PNU-282987 directly to the rat eyes. Removed tissue was sent to the Michigan
Innovation Center of Kalamazoo for LC/MSMS detection of PNU-282987.

These

time intervals corresponded to those that were done in the rabbit retina with the same
compound (Linnb et al., 2011).
Results from LC/MSMS studies demonstrated that all three doses of PNU282987 reached the retina. Figure 22 demonstrates the results from LC/MSMS
studies. The control bar measured from untreated retinal tissue indicates a low level of
structures similar to PNU-282987, averaging 0.6 ngPNU/gm (± 0.15). PNU-282987
does not exist physiologically in the body, but the assay detected similar compounds
that have a very similar chemical structure. The highest amount of PNU-282987
detected in the retina for any time interval was recorded at 2 hours. Two hours after
application, LC/MSMS detected 2.1 ngPNU/gm (± 0.25) in the retina after 100 µM
eye drops were used, 3.35 ngPNU/gm (± 0.41) after 1 mM eye drops were applied and
3.40 ngPNU/gm (± 0.38) after 10 mM PNU eye drops were applied. Each of these
values 2 hour calculations were significantly different from all other time intervals for
each particular concentration. PNU-282987 detection is the lowest at 12 hrs.
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Figure 22
LC/MSMS results on the retina applying different concentrations of PNU-282987 for
different amounts of time. The bar graphs demonstrate LC/MSMS results obtained
from the Michigan Inovation Center of Kalamazoo on retinal tissue using different
concentrations of PNU-2829897. * represents significant differences of PNU-282987
detection when eyes were treated with 100 µM PNU-282987 for 2 hours compared to
all other time points gathered using 100 µM PNU-282987. # represents significant
differences of PNU-282987 detection when eyes were treated with 1 mM PNU282987 for 2 hours compared to all other time points gathered using 1 mM PNU282987. ^ represents significant differences of PNU-282987 detection when eyes
were treated with 10 mM PNU-282987 for 2 hours compared to all other time points
gathered using 10 mM PNU-282987. Each bar graph was generated from Ns of 3-6.
Error bars represent SEM.

LC/MSMS experiments were also conducted on the vascular components of
the rat to determine if traces of PNU-282987 were found in the plasma and heart
tissues after eye drop application. Samples or retina, blood plasma, and heart tissue,
(separated into atria and ventricle) were collected in lab and sent to the Kalamazoo
Innovation Center for analysis after 10 mM PNU-282987 was applied as eye drops for
various amounts of time. The results of these studies are shown in Figure 23.
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The

highest levels of PNU-282987 were measured in the retina when 10 mM PNU-282987
was applied for 2 hours and was followed by a steady decrease in detection up to 12
hours. Cooresponding to results shown in Figure 22. Significantly lower levels of
PNU-282987 were detected in blood plasma, but levels in blood plasma peaked at 2
hours, similar to the peak measured in the retina.

Two hours after eye drop

application of 10 mM PNU-282987, only 0.35 ngPNU/gm (± 0.15) was detected in
the blood plasma. No trace amounts of PNU-282987 were found in the heart tissue at
any time points.

.
Figure 23
LC/MSMS results on the retina, blood plasma, and heart tissue using 10 mM PNU282987 at different time points. The line graphs demonstrate LC/MS MS results
obtained from the Kalamazoo Innovation Center on different tissues using PNU282987. Each data point represents the average obtained under each condition. Each
bar graph was generated from Ns of 3-6. Error bars represent SEM
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DISCUSSION

In this thesis, I report on investigations of the possible neuroprotective effects
of PNU-282987 administered as eye drops to prevent the loss of RGCs mediated
through α7 nAChRs using an in-vivo rat glaucoma-like model. In this study, it was
observed that an increase in IOP caused by injection of 2M NaCl into the episcleral
veins significantly reduced RGC density in the periphery of the RGC layer after one
month (26% RGC loss), and when PNU-282987 was applied as eye drops before and
after the hypertonic saline injection, it reached the retina and prevented loss of RGCs
due to hypertonic injections in a dose-dependent manner. For instance, 100 µM eye
drop concentration of PNU-282987 did not provide significant neuroprotection
against loss of RGCs normally associated with the procedure to induce glaucoma,
while 500 µM eye drop concentration of PNU-282987 provided significant
neuroprotection of RGCs in the retina (8.4% RGC loss), and 1 mM eye drop
concentration of PNU-282987 provided near complete neuroprotection of RGCs in
the retina (6.9% RGC loss). Surprisingly, it was also determined that 10 mM PNU282987 eye drop application significantly increased the percentage of RGCs when
compared to the control untreated eye (13.5% RGC gain). Overall, these results
strongly support the hypothesis that eye drop application of the α7 nAChR agonist,
PNU-282987, can prevent loss of RGCs associated with an increase in IOP in a dosedependent manner.
It was also determined that the remaining RGC somata that survived
hypertonic saline injections to induce glaucoma remained the same size even though
many of the cells displayed a blebbed membrane appearance. The diameter of RGC
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somata also did not change when treated with PNU-282987 before and after
glaucoma-like conditions caused by injection of hypertonic saline. The diameter of
main axon fascicles decreased under hypertonic saline injection conditions with no
PNU-282987 treatment but remained the same diameter if treated with PNU-282987
before and after hypertonic injection to induce glaucoma-like conditions. In addition,
analysis of defasciculation in the retina revealed that axons defasciculated off the
main fascicles when eyes underwent hypertonic saline injections that generated a
glaucoma model. However, this defasciculation did not occur if eyes were treated
with PNU-282987 before and after the glaucoma-inducing procedures. Morphological
analysis in control and glaucoma-like conditions in the retina are important to
understand the possible manifestations of experimentally-induced glaucoma.
LC/MSMS studies demonstrated that when PNU-282987 was applied as eye
drops; it can be detected and measured in the retina. This observation strongly
supports the hypothesis that eye drop application of PNU-282987 can be used to
prevent loss of RGCs associated with glaucoma-like conditions. LC/MSMS studies on
the heart (atria and ventricles) and blood plasma indicated no detectable levels of
PNU-289287 in the heart after eye drop application and relatively small amounts of
were detected in the blood plasma.

Cell Death Caused by Over-stimulation of Receptors

It is important to note that there are many factors that may contribute to the
manifestation of experimentally-induced glaucoma. A number of studies have argued
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that cell death caused by over-stimulation of receptors play a role on the onset of
glaucoma (Onley, 1969; Neal et al., 1994; Vickers et al., 1995; Kaushik, 2003), but
different contributing mechanisms are also likely to play a role in the progression of
the disease such as oxidative stress by reactive species, vascular dysregulation,
cytoskeletal dysfunction, changes in growth factor levels, genetic contributions, and
many other pathological pathways (Kuehn et al., 2005; Agarwal et al., 2009).
Manifestation of glaucoma and other neurodegenerative diseases is unclear, but it is
agreed that the primary risk factor associated with glaucoma is an increase in IOP
(Gelatt et al., 1977; Morrison et al., 1997; Chauhan et al., 2002; Levkovitch-Verbin et
al., 2002), leading to the degeneration of the optic nerve. The mechanisms behind this
process seem to be pathologically multifactorial and synergize with each other.
Although there are many contributing factors, the mechanisms for cell death caused
by over-stimulation of receptors remain to be explored and understood during
pathological manifestations.
This study draws many parallels with previous work in our laboratory.
Previous in-vitro experiments conducted in the rat retina have demonstrated the
effects of glutamate-induced cell death on isolated RGCs. Iwamoto (2011)
demonstrated that when glutamate was applied to cultured rat RGCs resulted in
significant cell loss. Loss of RGCs was also observed from glaucoma-like conditions
generated by hypertonic saline injections and lends support to the hypothesis that cell
death may be mediated by over-stimulation of receptors may also be involved in
glaucoma-like conditions in-vivo.
Results from this study also are in agreement with the effectiveness of the
hypertonic saline injection to produce glaucoma-like conditions that result in a
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decrease of RGCs in the rat retina (Birkholz, 2011; Iwamoto, 2011) as well is in other
laboratories (Morrison et al., 1997; Bouhenni et al., 2012). This consistency
demonstrates that the methods initiated by Morrison et al. (1997) are appropriate to
analyze RGC loss in an experimentally-induced model of glaucoma.
The mechanism of cell death due to glutamate on rat RGCs is still under
investigation. Previous studies have shown that excessive amounts of glutamate in the
eye leads to prolonged influx of cations, particularly calcium, in RGCs and causes
cellular cascades that lead to apoptosis and loss of visual function (Quigley, 1998;
Lam et al., 1999; Asomugha et al., 2010; Brandt et al., 2011). Previous studies from
this lab have linked overstimulation of glutamate receptors in the pig retina to
activation of the P38 MAPK pathway leading to apoptosis. Activation of this kinase
was proposed to begin apoptotic mechanisms by blocking BCl2, thereby inhibiting the
anti-apoptotic role of BCl2 (Asomugha et al., 2010). Similar investigations must be
conducted in rat RGCs in-vitro to investigate the apoptotic pathway that may be
activated during similar conditions as these mechanisms can differ between different
models.
Many neurodegenerative diseases, including glaucoma, have been linked to
cell death mediated by over-stimulation of receptors. A mechanistic understanding of
cell death caused by over-stimulation of receptors in these diseases may lead to
preventative and therapeutic measures to prevent neuropathy. There are many
neurotransmitters found in the CNS that may contribute to homeostasis.

When

concentrations of these agents are disturbed, it can prolong or diminish the signaling
from ligand-gated ionotropic receptors causing cell death mediated by apoptotic
pathways (Dunnet, 1999; Doble, 1999; Page et al, 1999; Agarwal et al, 2009; Seidl
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and Potashkin, 2011). Parkinson’s disease, among many other neurodegenerative
diseases, may be associated with cell death caused by over-stimulation of receptors as
part of their pathological manifestation. Parkinson’s disease is characterized by a
selective loss of dopaminergic neurons which lead to inhibitory output to the thalamus
caused by degeneration of the substantia nigra, resulting in motor dysfunction
(Prezedborski, 2005). Substantia nigra cells contain NMDA receptors and receive
input from the subthalamic nucleus in the form of glutamate. As substantia nigra
neurons degenerate, the stimulation from the subthalamic nucleus is not restrained and
further induces cell death in nigral cells, resulting in progressive neuronal
degeneration (Simon et al., 2002). In Alzheimer’s disease, cell death caused by overstimulation of receptors may be manifested by an over abundance of β-amyloid
peptides that follow a cellular cascade which ultimately results in stimulation of
NMDA receptors, causing a high influx of calcium in the cell and leading to cell death
(Miguel-Hidalgo et al., 2002).
The mechanisms involved with cell death caused by over-stimulation of
receptors in other neurodegenerative diseases seem to be linked to glutamate-induced
apoptosis mediated through ligand-gated NMDA receptors, parallel to glaucoma-like
models (Manev et al., 1989; Aarts and Tymianski, 2004; Wang et al., 2010). In
Alzheimer’s disease some weak nonselective NMDA receptor antagonists have been
shown to increase functionality (Gortelmeyer and Erbler, 1992). Other studies in
Parkinson’s disease have used similar antagonists on NMDA receptors such as
procyclidine, amantadine, budipine, and memantine. These compounds have been
shown to also increase functionality in individuals (Onley et al., 1987; Rabey et al.,
1992; Jackisch et al., 1994), though no treatment can prevent cell loss entirely.
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Future in-vivo studies in a rat glaucoma model need to include focus on
mechanisms of cell death and neuroprotection associated with glaucoma-like
conditions. A potential way to check that cell death mediated by over-stimulation of
receptors is to use specific glutamate antagonists such as MK-810 that would target
NMDA receptors. This may support that glutamate-induced cell death may be
mediated by excessive abundance of glutamate through NMDA receptors. If RGC
degeneration is inhibited, it would support previous studies that were done in-vitro.
This could be repeated in-vivo to retain consistency and further support that
glutamate-induced cell death is involved in glaucoma-like conditions. Another way to
support previous in-vitro studies is to use ELISA techniques in-vivo. This could
demonstrate the up or down regulation of apoptotic markers, analogous to the work
done by Asomugha et al. (2010) that analyzed the apoptotic and cell survival
pathways in-vitro. These results may draw parallels with previous work if performed
in-vivo and give insights to possible mechanisms involved during cell death and
neuroprotection during glaucoma-like conditions.

Neuroprotection

As previously mentioned, many neurodegenerative diseases have been
associated with over-stimulation of receptors resulting in cell death. Neuroprotection
against the over-stimulation of receptors has been used as a therapeutic approach in
many neurodegenerative diseases, including glaucoma. In this study I analyzed the
neuroprotective effect of PNU-282987, a α7 nAChR-specific agonist, to determine if
it can prevent loss of RGCs caused by a glaucoma-inducing procedure. Results using
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this particular agonist showed a dose-dependent response to prevent death of RGCs
during glaucoma-like conditions. Increasing the concentration of PNU-282987
showed significant improvement in glaucoma-like conditions with every increasing
dose. Previous in-vitro work in the pig and rat retina demonstrated that when nAChR
agonists were applied, such as nicotine and ACh during glaucoma-like conditions,
provided a protective effect to inhibit the degeneration of cultured RGCs (Wehrwein
et al., 2004; Asomugha et al., 2010; Birkholz, 2011; Iwamoto, 2011). Other studies
using a α7 nAChR antagonist, MLA, demonstrated that the neuroprotective effect was
mediated through α7 nAChRs. This is consistent with previous in-vivo experiments
using PNU-2827987. When PNU-282987 was injected intravitreally, it provided
neuroprotective effects to prevent loss of RGCs during glaucoma-like conditions,
similar to those in this study using eye drop application (Iwamoto, 2011).
Previous in-vitro studies from this laboratory have suggested mechanisms for
neuroprotection against glutamate-induced RGC death in the pig retina. ELISA
studies

demonstrated

that

ACh

activation

of

α7

nAChRs

triggered

phosphatidylinositol-3-kinase (P13). This activation of P13 phosphorylated Akt to
activate BCl2 and provided neuroprotective effects against glutamate-induced RGC
death (Asomugha et al., 2010). The activation of this neuroprotective pathway was
found to be initiated by calcium influx through α7 nAChR channels (Brandt et al.,
2011). However, calcium influx through glutamate-activated NMDA receptors is also
thought to be the main cause for RGC death in glaucoma models by over-stimulation
of receptors. As discussed in Brandt et al. (2011), it was proposed that a
preconditioning dose of calcium entering through the nAChRs triggered the
neuroprotective pathways and preconditioned the cells against a subsequent larger
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calcium influx. This preconditioning dose of calcium appears to be the main correlate
of neuroprotective effects in these models.
The α7 nAChR is one of the main receptors that play a role in neuroprotection
against neurodegenerative diseases in the brain (Conejero-Goldberg et al., 2008; Liu
et al., 2012). Here, results are presented that support the hypothesis that α7 nAChRs
are also involved in neuroprotection in a generated glaucoma model.

However, does

neuroprotection against RGC loss occur under physiological conditions in the retina?
Starburst amacrine cells are a type of amacrine cells that release ACh under
normal conditions onto RGCs (Famiglietti, 1983; Massland, 1988; Grimes, 2011). It is
possible that ACh release may be compromised under a glaucoma-like environment.
This reduction in ACh may contribute to the loss of RGCs normally associated with
glaucoma-like conditions. The justification for this proposition is that ACh has been
found to have a neuroprotective effect in cultured cells (Wehrwein et al., 2004). If
activation of AChRs has a neuroprotective role under physiological conditions, it
should help to prevent cell death under glaucoma-like conditions that are mediated by
over-stimulation of receptors. If the starburst amacrine cells are also lost under
glaucoma-like conditions or if the release of ACh from them is compromised, it would
unveil a previously unknown function of starburst amacrine cells in the retina. I
propose that ACh release is reduced in glaucoma conditions. This remains to be
determined. If true, neuroprotective role of ACh would be compromised in such a way
that it induces loss of RGCs since there is an insufficient amount of ACh. In this
study, activation of α7 nAChRs prevents loss of RGCs associated with glaucoma-like
conditions in a rat glaucoma model, supporting the hypothesis that ACh levels may be
compromised under glaucoma-like conditions. If future studies find that ACh has a
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neuroprotective effect in the retina under normal conditions, it could greatly enhance
our understanding of the retina and our appreciation of different ways that the retina
naturally protects the RGC layer. Future work to investigate this possible function
includes labeling of ACh with radiolabelled choline to assess the amount of the
neurotransmitter in the retina during normal physiological conditions and glaucomalike conditions. Once ACh is labeled, perfusates could be collected from control
eyecups in response to light and from glaucoma-like eyecups in response to light. The
amount of ACh released under each condition could be compared. If ACh content is
reduced during glaucoma like conditions, it may be that starburst amacrine cells have
compromised ACh release, since they are one of the few neurons in the retina known
to release ACh. This would support that RCG cells may be receiving neuroprotective
input from the starburst amacrine cells under normal physiological conditions.

Increased RGC Density Using PNU-282987

This particular study had unprecedented results using 10 mM PNU-282987 on
a glaucoma-like model. This model demonstrated dose-dependent results using PNU282987. The lowest dose of 100 µM PNU-282987 had no significant effects, while
500 µM PNU-282987 and 1mM PNU-383987 had visible neuroprotective effects
leading to enhanced RGC survival when compared to the internal control. However,
when 10 mM PNU-282987 was applied as eye drops, RGC counts increased by an
average of 13.5% (+/-4.19; N=5) when compared to the internal control. This was a
surprising result, as adult retinal neurons do not typically divide.
This increase in cell density had been observed in previous work using PNU68

282987 and nicotine administration. In these in-vivo rat studies, cells in the RGC
layer were stained using cresyl violet staining which allowed visualization of all cell
bodies in the RGC layer (Birkholz, 2011 and Iwamoto 2011). However, as cresyl
violet stains the nuclei of all cells in the RGC layer, it was uncertain if the increase in
cell counts were due to an increase of RGCs. However, in this thesis, only RGCs
were labeled by using the specific Thy 1.1 antibody. This suggests that the cell
increase observed in the cresyl violet stained retinas may be due to an increase of
differentiated RGCs.
The reason behind this apparent paradox remains unknown. There are many
possible explanations for this outcome including, but not limited to; an increased
expression of glycoprotein Thy 1.1 in other neurons due to unknown molecular
factors, relatively high doses of PNU-282987 could cause mitotic dysfunction
resulting in cancerous effects, or the dose of PNU-282987 used could cause
stimulation of neuronal growth in the retina. This phenomenon was an unexpected and
drawing any detailed conclusions would be premature. Studies are now investigating
this perplexing, but exciting, observation. The work begun to assess this increase in
RGCs includes double labeling experiments to ensure that the Thy 1.1 antibody is in
sync with a different RGC marker. Other potential work to investigate increased RGC
density includes using cell death markers, such as caspases-3 antibodies or TUNEL
assays that label apoptotic cells. By labeling cells with cell death markers, we can
gain an insight into what is happening in the glaucoma model used in our laboratory.
A key future study is to use fluorescent staining against cell proliferating markers.
PCNA (proliferating cell nuclear antigen) and BrdU (Bromodeoxyuridine) have begun
to be used to examine the cellular proliferation that could be occurring.
69

Neural Morphology

Axon fascicle characterizations in the rat retina during glaucoma-like
conditions have yet to be investigated and characterized using antibody against Thy
1.1. Previous work from our laboratory has not investigated the retinal organization
using this particular method to label RGCs. By analyzing this morphology during
normal and glaucoma-like conditions we may provide insight into the manifestation
of experimentally-induced glaucoma. Results from this study have shown that RGC
axon fascicle diameter changes under different conditions during a glaucoma-like
environment. This study has shown the dose-dependent response of PNU-282987
under glaucoma-like conditions induced by injections of hypertonic saline. This study
shows that RGC axon fascicle diameter decreases when injected with hypertonic
saline. This decrease in diameter supports the observation that RGC density decreases
during glaucoma-like conditions. If RGCs are degenerating during glaucoma-like
conditions, their corresponding axons filaments would also subsequently degenerate,
decreasing the diameter of the fascicle, as expected. Similar results have been shown
to display a marked correlation between RGC death and axon degeneration (Trip et
al., 2005; Soto et al., 2011; Kalesnykas et al., 2012). However, when a dose of 10 mM
PNU-282987 was used, the degree of degeneration in axon fascicle diameter
decreased. In glaucoma-like conditions, RGC axon fascicle diameter decreased 25%
when compared to the diameter of axon fascicles in the internal control of the same
animals. When 10 mM PNU-282987 was used, axon fascicle diameter did not
demonstrate significant differences when compared to the internal controls of the
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same animals. This parallel between axon fascicle diameter and RGC counts support
the effects of the glaucoma-inducing procedure and the neuroprotective effects of
PNU-282987. Characterization of RGC axon fascicle diameter has never been
characterized in the rat retina during glaucoma-like conditions using Thy 1.1. The
diameter of axon fascicles 400 µm from the ONH ranged between 16-22 µm under
normal physiological conditions. Axon fascicle diameter changes 1 month following
hypertonic injections to induce glaucoma because RGC degeneration is the highest at
this point before retinal detachment is observed (Morrison et al., 1997). Loss of RGC
components include the loss of RGC axons, which make up the main axon fascicles
that make up the optic nerve. Variations in this diameter can fluctuate significantly as
measurements can increase towards the ONH and decrease away from the ONH.
However, measurements were only made 400 µm from the ONH. Future studies need
to be conducted to get an accurate representation of the RGC axon fascicle diameter
in the rat retina at different distances from the ONH.
The change in axon fascicle diameter is consistent with other studies that
characterize the composition of the optic nerve during experimental glaucoma.
Various manipulations and techniques to induce glaucoma-like conditions have shown
that optic nerve damage is visibly seen under experimental glaucoma models (Quigley
et al., 1987; Fetchner and Weinreb, 1994; Mabuchi et al., 2004). Although this study
did not include optic nerve histology, as it only focused on activity in the retina, the
degeneration of the RGCs and the loss of corresponding axons are parallel to damages
that are seen in the optic nerve showing a marked decrease in optic nerve filaments
and axonal death (Quigley et al., 1987; Fetchner and Weinreb, 1994; Mabuchi et al.,
2004).
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In the retina, defasciculation from the large axon fascicle bundles was also
observed after hypertonic saline injections to induce glaucoma-like conditions.
Defasciculation during glaucoma like conditions using PNU-282987 resulted in less
defasciculation from main axon fascicles. The increase of defasciculation during
glaucoma-like conditions and prevention of this process using PNU-282987 treatment
corresponds to the decrease in axon fascicle diameter and then recovery of the axon
fascicle diameter. This relationship has not been previously characterized and suggests
that when RGCs are lost, or in the process of degenerating, there is a more complex
cascade of damage that extends to the optic nerve than previously expected. When
RGCs are lost, the main axon fascicle diameter decreases. This could be due to both
the axonal defasciculation and death and subsequent loss of axons that is occurring at
the RGC soma level. Different studies have observed defasciculation in the optic
nerve during glaucoma-like conditions that also occurs with RGC loss and
degeneration of optic nerve myelin (Fu and Sretavan, 2010; Soto et al., 2011). This
observation may tie to other mechanisms that may be involved with the onset of
experimentally-induced glaucoma. Onset of axon degeneration may be an early event
during the manifestation of glaucoma and could be associated with degeneration of
supporting proteins that bundle axon fascicles (Fu and Sretevan, 2010). Additionally,
this correlation may be associated with myelin-degenerating diseases such as multiple
sclerosis (Fu and Sretevan, 2010). Defasciculation of RGC axons and optic nerve may
play a very important role in the manifestation of glaucoma that is currently not well
investigated.
Among the fascicular changes in the retina during glaucoma-like conditions,
morphological differences were also observed in the RGC somata. Blebbing of the
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RGC membrane after hypertonic saline injections was also observed in this study. The
blebbing of the RGC membrane was diminished as increasing doses of PNU-282987
was administered before and after hypertonic injections. Blebbing is defined as
protrusions of the cell membrane (Charras, 2008) and can manifest in a number of
instances including apoptosis (Mills et al., 1999 and Coleman et al., 2001). Blebbing
of RGCs may demonstrate the execution phase of apoptosis during glaucoma-like
conditions generated by injection of hypertonic saline and may support that RGC loss
may be mediated by apoptosis associated in experimentally-induced glaucoma
(WoldeMussie et al., 2001; Levkovitch-Verbin et al., 2002). This would support
current proposed mechanisms that associate the manifestation of experimentallyinduced glaucoma with apoptosis (Kerrigan et al., 1997; Quigley, 1999).
It is proposed that soma size decreases under apoptotic events (Kerr et al.,
1972). With this knowledge in mind, it has been reported that although RGCs are the
main cell type susceptible in glaucoma-like conditions, larger RGCs with larger axon
diameters seem to degenerate before any other RGC type in human, primate, feline,
and other animal glaucoma models (Kalensnykas et al., 2012). RGC characterizations
during glaucoma-like manipulations have not been well investigated or understood.
From this study, it was shown that the diameter of the remaining RGC somata
remained consistent throughout different manipulations.

However, there was a

blebbed morphology observed in the plasma membrane of RGCs one month
following hypertonic saline injections to induce glaucoma. Although RGC diameters
remained consistent in various manipulations it is important to note that RGCs have
already gone through apoptosis and can’t be counted as apoptotic remnants would
have been phagocytized. The blebbing in the remaining cells might indicate the
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beginning of the onset of apoptosis in remaining cells.
Initially, I expected to find a decrease in RGC diameter during glaucoma-like
conditions due to the glaucoma-like conditions existing in the eye.

However, the

results of this study 1 month after hypertonic injections demonstrate similar RGC
soma diameters when compared to the internal controls. Similar results characterizing
RGC soma size under glaucoma-like conditions has also been shown in other studies
demonstrating no change in RGC soma size (Pavlidis et al., 2003). Although similar
results have been achieved, different studies have also shown that there seems to be a
discrepancy in the characterization of RGC soma size under experimental glaucoma
models. Studies have shown an increase in RGC soma size (Ahmed et al., 2003) and
decrease in RGC soma size (Jacobs et al., 2005; Kalesnykas et al., 2012) in glaucoma
models. It is likely that the different results obtained from different researchers
correspond to time tissue is sacrificed and processed. If tissue is processed early in
the apoptotic process, more cells may appear smaller if they haven’t been
phagocytized. On the other hand, cells may appear to be similar in size if all cells that
are destined to go through apoptosis have done so already before processing the
tissue. Under this scenario, the remaining cells would likely not be affected.

Applications

In this study, the neuroprotective effect of the α7 nAChR agonist, PNU282987, has been tested to show that it inhibits the loss of RGCs in glaucoma-like
conditions in a dose-dependent manner. It was observed that in order to prevent the
degeneration of RGCs, a pretreatment of PNU-282987 was necessary to provide
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neuroprotective effects against a glaucomatous environment. No neuroprotection
occurs if an agent was given at the same time or after the glutamate insult to prevent
loss of RGCs (Wehrwein et al, 2004; Iwamoto et al., 2011). Clinically, this introduces
a preventative approach to avoid the onset of glaucoma in patients that might be
susceptible to the disease based on genetic probability, race and/or family history. To
date, all glaucoma treatments are designed to decrease IOP measurements (Cairns,
1968; Damji et al., 2003). The results from this study could change the way that
glaucoma may be treated as PNU-282987 treats the disease at the retina level instead
of in the anterior chamber of the eye. Previous work by Iwamoto et al., (2011) used
intravitreal injections of PNU-282987 to deliver the compound directly into the eye.
This was an invasive method and was unappealing for therapeutic development. The
application of PNU-282987 by eye drops used in this thesis provides greater appeal
for preventative treatment and potential development for glaucoma patients.
A primary concern for these new neuroprotective compounds in the nervous
system is their potentially harmful effects to other tissue. Introduction of these
compounds may have hazardous effects on other systems in the body as there are α7
nAChRs in many organs throughout the body. PNU-282987 was initially developed
by Pharmacia and Upjohn to treat Schizophrenia. However, its use was discontinued
to treat Schizophrenia as systemic application reached the vascular system and the
heart. In the heart, PNU-282987 was found to inhibit a potassium channel thus
diminishing its development to treat the disease.
To circumvent this issue, PNU-282987 was applied as eye drops in this study
and was not applied systemically. As a result, it seemed likely that PNU-282987
would not reach the heart and initiate damage. To confirm this, LC/MSMS results
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demonstrated that PNU-282987 levels were detected and measureable in the rat retina
when the agent was applied as eye drops and remained detectable for at least 12 hrs.
Delivery of PNU-282987 to the retina by topical eye drops has also been detected in
the rabbit retina and shown to stay in the eye for at least 8 hrs (Linn et al., 2011). This
is more than enough time to trigger cell survival pathways (Asomugha et al., 2010).
In addition, relatively low levels of PNU-282987 were detected in blood plasma and
no PNU-282987 was detectable in the atria or ventricles of the heart. As a result,
application of PNU-282987 may be developed as a pretreatment for diseases where it
can be applied topically.

Implications and Future Studies

The main purpose of this study was the test the hypothesis that the α7 nAChR
agonist, PNU-282987, had a neuroprotective effect against RGC loss in an
experimentally-induced glaucoma rat model. Results demonstrated that RGCs had a
significant survival rate under glaucoma-like conditions if rats were treated with
PNU-282987 for 3 days before the hypertonic injections and after one month
following hypertonic injections to induce glaucoma-like conditions. The mechanism
behind this neuroprotective effect remains unknown, but one hypothesis based on
previous in-vitro studies is that overstimulation of glutamate receptors results in
apoptosis under glaucoma-like conditions. The same cellular response could be
occurring in the rat model in response to over stimulation of glutamate receptors, but
future studies are needed to confirm this. Similarly, neuroprotective pathways using
ACh and respective agonists could trigger P-I3 kinase to begin an intracellular
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cascade to promote cell survival (Alvarez et al., 2009 and Asomugha 2010). Other
peptides, such as brain-derived neutrophic factor, have also been shown to also
activate the P13 kinase pathway to prevent death of RGCs (Nakazawa et al., 2002).
This cell survival pathway by P13 kinase has been linked to calcium influx that is
mediated through nAChRs to protect pig RGCs in-vitro (Brandt et al., 2011). I
propose that preconditioning of a relatively low amount of calcium, by activation of
the α7 nAChR agonist, PNU-282987; prior to hypertonic saline injection can provide
neuroprotective effects by activating an intracellular survival pathway. This cell
survival pathway may be similar to the P13 kinase pathway that is shown in the
porcine model. I propose that similar pathways leading to apoptotic events could be
similar as the pathways identified in the porcine model under conditions using
hypertonic saline injections to mimic glaucoma-like conditions. These inferences are
untested at present. However in the in-vivo rat model and future studies must be
shown to determine the molecular mechanisms in the rat model that are responsible
for RGC death and survival under glaucoma-like conditions.
An array of analyses was conducted to characterize the retinal components in a
glaucoma-like rat model. Analysis looking at RGC axon fascicle diameter matched up
with predictions. Diameter from main axon fascicles 400 µm from the ONH
decreased under glaucoma-like conditions.

This decrease in diameter was

significantly reduced if eyes were treated with 10 mM PNU-282987 before and fater
hypertonic saline injections to generate a glaucoma model. Results from this study
also indicated defasciculation from the main axon fascicles under glaucoma-like
conditions increased from internal control conditions and was directly correlated with
a decrease in axon fascicle diameter, but this decrease was less prevalent when treated
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with PNU-282987. RGC soma size was expected to decrease under glaucoma-like
conditions and remain a normal size when treated with PNU-282987 compared to
their internal controls. Instead, we found that RGC soma size was virtually the same
before and after the procedure to induce glaucoma.

This result could be due to

apoptotic cells already having been phagocytized. Additionally, it was observed that
RGCs had a blebbed appearance during glaucoma-like conditions. Blebbing is
common during apoptotic processes and gives an insight to what could be
mechanistically occurring during glaucoma-like conditions in the retina.
From previous studies it has been shown that ACh provides neuroprotective
effects in isolated pig RGCs. The hypothesis first introduced by Iwamoto (2011)
remains at question if ACh release from amacrine cells is compromised during
glaucoma-like conditions. Studies have demonstrated that RGCs are the main target in
cell loss in glaucoma. However, a subset of cholinergic starburst amacrine cells are
displaced amacrine cells that are also found in the RGC layer and may be affected by
glaucomatous conditions. If ACh does in fact provide neuroprotective effects in
normal physiological states, it may be that ACh release is compromised in glaucoma.
Almasieh et al. (2010) has demonstrated the effects of acetyl cholinesterase (AChE)
using galantamine, an AChE inhibitor, to provide neuroprotective effects in glaucoma
models. This further supports the hypothesis that ACh levels may decrease in
glaucoma. It could also be noted that the introduction of hypertonic saline to produce
glaucoma-like conditions may be altering the amount of affinity of the receptors that
are present on RGCs that may compromise the neuroprotective role of ACh. There are
other propositions on why normal neuroprotective effects that occur physiologically
are compromised. One of these propositions include that this compromise of ACh
78

release may be due to other outside factors that are indirectly effecting the normal
release of ACh from amacrine cells. Another possibility includes the internalization of
cholinergic receptors may be occurring due to the conditions that exist in glaucoma.
This internalization of receptors may ultimately be affecting the effects of ACh on
RGCs during glaucoma-like conditions (Shen et al., 2010). Future studies must be
conducted to investigate the roll of ACh in glaucoma and determine its effect.
PNU-282987 has been shown to have a neuroprotective effect on RGCs when
subject to hypertonic injection of saline, but the functionality of the surviving RGCs
remains unknown. Although these cells remain visible under the microscope, it is
important to verify that these neurons are still capable of producing electrical currents
using electrophysiology techniques to assure that there are no changes in ion channel
activity in response to the administration of PNU-282987. Following these
electrophysiology studies, behavioral studies may be conducted to confirm if there are
any changes in visual acuity, contrast detection or directional selectively in the rat
model. These behavioral studies will further the appeal the use of α7 nAChR agonists
for therapeutic uses in the mammalian retina.
Using 10 mM PNU-282987 caused a significant increase in RGC counts when
compared to the other doses that were administered. This unprecedented phenomenon
was also observed by Birkholz (2011) and Iwamoto (2011) from this laboratory. Many
studies must be done to fully understand these observations.
PNU-282987 was initially used to treat schizophrenia and deemed to be unsafe
due to traces of the compound effecting ion channels in the heart. The introduction of
this compound in the visual system has been successful and demonstrated that it can
prevent loss of RGCs during experimental glaucoma. LC/MSMS studies indicate that
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PNU-282987 reaches the retina when applied as eye drops, similar to results in the
rabbit retina (Linn et al., 2011). Traces of PNU-282987 were not found in the heart
and only relatively small traces were found in the blood plasma. Longer timelines
must be developed to ensure that PNU-282987 administration will not have similar
results as the trials conducted in schizophrenia models.
The results of PNU-282987 in culture studies and in-vivo have shown to have
promising effects in preventing nerve damage associated with experimentally-induced
glaucoma models. The use of PNU-282987 may be applicable in medical settings to
prevent RGC loss typically associated with glaucoma. Long term use of this agent
may have potential to be used as a preventative treatment for individuals that may be
susceptible to RGC degeneration in ocular neuropathies.
In conclusion, the data presented in this study demonstrate the potential of α7
nAChR agonists, including PNU-282987, to significantly prevent the loss of RGCs
associated with experimental glaucoma and possibly with glutamate-induced cell
death. Results from this study also support the potential of nAChRs to be used as a
target in other neurodegenerative diseases, including glaucoma, to decrease the
probability of neuronal dysfunction.
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